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ZUSAMMENFASSUNG
Exosome sind kleine Vesikel, die von den meisten Zellen eines Organismus
produziert werden und als das wichtigste interzelluläre Kommunikationsmittel
diskutiert werden. Tumorzellen sezernieren besonders viele Exosomen. Da sich
Exosomen im gesamten Organismus verteilen, können Tumorexosomen sowohl
mit benachbarten Tumorzellen, tumorassoziierten Wirtszellen und mit entfernten
Zellen, z.B. hämatopoetischen Zellen, vaskulären Endothelzellen und
verschiedenen Stromazellen, kommunizieren. Es ist bekannt, dass die
Kommunikation zwischen Zellen und Exosomen hauptsächlich über
rezeptorvermittelte Signaltransduktion nach Bindung der Exosomen und durch
Reprogrammierung der Zielzelle nach Übergabe des exosomalen Kargos in die
Zielzelle, erfolgt. Hingegen gibt es kaum Informationen über den Einfluss von
Tumorexosomen auf die extrazelluläre Matrix, die aber einen wichtigen
Bestandteil des Tumormikromilieus darstellt. Daher fragte ich, ob
Tumorexosomen auch die Organisation der extrazellulären Matrix beeinflussen
und ob diese Veränderungen auf Stromazellen und Tumorzellen rückwirken.
Als Modellsystem verwendete ich Exosomen der metastasierende
Pankreastumorzelllinie ASML der Ratte und eine schwach metastasierende
ASML-CD44v6 knockdown Linie. Ich konnte zeigen, dass
I) Tumorexosomen im gesamten Organismus an Komponenten der
extrazellulären Matrix binden.
Die bevorzugten Bindungspartner hängen vom Expressionsprofil an
Adhäsionsmolekülen der Tumorexosomen ab. ASML Exosomen, die eine hohe
CD44- und α4β6-Expression aufweisen, binden bevorzugt an Hyaluronsäure und
Laminin 332.
II) Tumorexosomen die extrazelluläre Matrix verändern.
Kollagen, Laminin, Fibronektin und native Matrizes werden durch exosomale
Proteasen degradiert. Die höhere Effizienz des Matrix Abbaus durch ASML im
Vergleich zu ASML-CD44v6 knockdown Exosomen beruht auf der durch
CD44v6 unterstützten Transkription von uPAR und der Assoziation von
CD44v6 mit MMP-9, MMP-14 und TACE.
Zusammenfassung
XI
III) die durch Tumorexosomen modulierte Matrix Stromazellen und
hämatopoetischen Zellen beeinflusst.
Der Matrixabbau durch Tumorexosomen beeinflusst Adhäsion, Migration und
Invasivität, sowie Proliferation und Apoptoseresistenz von Stromazellen. Dies
ist zumindest teilweise auf die Generierung bioaktive Abbauprodukte der Matrix
und die Freisetzung von Wachstumsfaktoren und Chemokinen aus der Matrix
zurückzuführen.
Tumorexosomen binden und modulieren sowohl die Tumormatrix als auch die
extrazellulären Matrix entfernt liegender Organe. Die durch Tumorexosomen
modulierte extrazelluläre Matrix ist ein kritischer Faktor in der Kommunikation
zwischen Tumorzellen und dem Wirt. Dies schließt die Rekrutierung
hämatopoetischer Zellen und die Vorbereitung der prämetastatischen Nische ein.
Unter physiologischen Bedingungen könnte die Modulation der extrazellulären
Matrix durch Exosomen zu Organogenese, Vaskulogenese und Angiogenese
beitragen und bei Gewebereparatur wie Wundheilung und Koagulation nach
Verletzung von Blutgefäßen beteiligt sein.
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1. INTRODUCTION
Cancer remains a leading cause of death. This is mainly due to the capacity of
tumor cells to spread through the body and to settle in distant organs, which
process is called metastasis (Alberts et al., 2008; Jemal, et al., 2011). Metastasis
formation is tumor cells show additional genetic alterations that allow primary
tumor cell detachment, invasion and growth at distant site. Despite extensive
studies on tumor cell biology that provide many helpful suggestions on early
cancer detection and new treatment strategies, there are still many open
questions on tumor progression, drug resistance and settlement at distant sites
which are the major causes of the clinical failure in surgery or chemo- and
radiotherapy.
1.1 Pancreatic adenocarcinoma
Pancreatic cancer is characterized as an aggressive malignancy, with the poorest
diagnosis in gastrointestinal cancers. (Keleg et al., 2010). The cause of
pancreatic cancer so far remains unknown, but most common known risk factors
are smoking, high-calorie diet, chronic pancreatitis and diabetes (Jones et al.,
2008; Dumitrascu et al., 2009; Carney et al., 2003).
Pancreatic ductal adenocarcinoma (PDAC) could account for the large majority
(92%) of all pancreatic neoplasms. The estimated 5 years survival rate is less
than 6% (Michaud et al., 2007). PDAC originates in ductal epithelium and
evolves from pancreatic intraepithelial neoplasias (PanINs). This progression
from minimal grade PanIN-1 (low-grade) to more severe grades including
PanIN-2 (intermediate-grade) or -3 (high-grade), and finally to invasive
carcinoma, results from the successive accumulation of genetic alterations. The
lower grade PanIN-1 or -2 harbors genetic alterations in the GTPase KRas
(KRAS) (Dumitrascu et al., 2003; Alberts et al., 2008), and cyclin-dependent
kinase inhibitor 2A (p16/CDKN2A) (Brabletz et al., 2003), whereas the higher
grade PanIN-3 and invasive adenocarcinomas not only contain the genetic
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alterations in KRAS and p16/CDKN2A genes, but also specially harbor several
mutations in tumor protein p53 (TP53) and SMAD4 (Jones. et al., 2008).
Although great achievements have been made in pancreatic cancer research, it
remains the deadliest form of solid malignancy, and after metastatic spread there
are no effective therapeutics. As a matter of fact, lack of clinical symptoms still
results in poor early detection in PDAC patients. The high lethality of PDAC is
mainly due to the fact that most patients have advanced disease stages when
diagnosed, with the tumor rapidly spreading and being resistant to chemotherapy
and radiotherapy (Krautz et al., 2011). Thus, tumor metastasis will be the main
therapeutic target for patients with PADC when removal by surgery failed.
1.2 Tumor metastasis
Tumor metastasis is the spreading of cancer cells through lymphatic and blood
vessels from the organ where the cancer originates to other organs like bone,
lung and brain, which are not directly connected with the primary tumor organ
(Birchmeier et al., 2003; Brabletz et al., 2010). Tumor metastasis is responsible
for over 90% of the mortality rate in pancreatic cancer patients and is the most
life-threatening aspect of cancer (Fidler, 2003). Metastasis formation requires
cancer cells to escape apoptotic signals and to survive despite the host immune
responses (Hunter et al. 2008). Briefly, during cancer metastasis, cancer cells
first detach from the surrounding tumor cells and escape from the primary site,
migrate through the basement membrane, invade and penetrate through the
blood vessels or lymphatic channels, arrest in the circulation, extravasate into
secondary sites, finally adapt and outgrow in a new microenvironment (Figure
1).
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Figure 1.The development of malignant tumor cells including detachment, invasion, extravasation and
proliferation in a second organ. (Hunter et al. 2008)
Many theories already proposed to explain the process of tumor metastasis.
Among them, the ‘seed and soil’ hypothesis offers a great insight into the tumor
development and metastasis (Paget, 1889; Fidler, 2003). This hypothesis
supposes that the tumor cells (seeds) are disseminated systemically, but they can
only grow in specific organ microenvironments (soils).
Since then, the concept of the pre-metastatic niche has been proposed, which
states that the primary tumor cells can transmit signals to create an environment
prior to the arrival of metastatic cells (Alderton et al., 2012; Birchmeier et al.,
2003). It means that the ‘soil’ is prepared much earlier than expected in the
period of tumor carcinogenesis. In fact, before the migrating tumor cells
approach distant sites, the target organs already have been colonized by
myelomonocytic cells originating from the bone marrow (BM) (Erler et al.,
2009). These myelomonocytic cells form an inflammatory-like
microenvironment, which is similar to the cancer microenvironment that is
produced by the primary tumor, and promotes tumor cell settlement and survival
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in a new hostile environment (John et al., 2003; Castells et al., 2012). Thus,
elaborating the mechanisms underlying metastatic niche establishment can
substantially improve the early therapeutic targeting of disseminated tumor cells,
as well as the prognosis for patients with advanced malignancy.
To date, it is widely accepted that the cancer microenvironment is crucial for the
metastatic process including pre-metastatic niche formation. (Epifano et al.,
2004; Hunter et al., 2008). The cancer microenvironment is created by the
cancer cells and dominated by tumor stroma, blood vessels, tissue-associated
cells and infiltrating inflammatory cells (Stewart et al., 2011;Keleg et al., 2003).
Apart from the effect on tumor metastasis, there are emerging evidences
showing that the cancer microenvironment also promotes tumor initiation and
proliferation.
1.3 Cell-Extracellular matrix interactions
The extracellular matrix (ECM) is a mixture of extracellular molecules secreted
by cells, which provides biochemical and structural support to the surroundings
(Hynes et al., 2009; Kopfstein et al., 2006). The interaction between cells and
extracellular matrix components plays significant roles in regulating many
different cellular functions like cell motility, proliferation, differentiation and
drug resistance (Brizzi et al., 2012; Shields et al., 2012). In the context of cancer,
the extracellular matrix is the main component of the cancer microenvironment.
During cancer development, the extracellular matrix helps cancer cells to build a
niche and to establish a microenvironment that favor the growth of the primary
tumor and tumor metastasis. As the extracellular matrix has such a critical role
in tumor metastasis, clarifying cell-ECM interactions will contribute to the
understanding of cancer microenvironment and cancer progression.
1.3.1 Integrins
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Integrins present on the cell surface are the main receptors responsible for cell-
ECM interactions (Hakulinen et al., 2003). They are transmembrane proteins
containing transmembrane alpha and beta subunits, large extracellular domains
for the interaction with the ligands in the extracellular matrix and an intracellular
domain interacting with cytoskeleton proteins (Kawakami et al., 1999; Epifano
et al., 2012). In mammals, 18 alpha subunits and 8 beta subunits have been
characterized, and these subunits can combine in various ways to form 24
integrin receptors (Hynes, 2002). Integrins function as the mediator of the
extracellular signal when binding ligands to transmit chemical and mechanical
signals into the cytoplasm, which leads to the rearrangements of the
cytoskeleton and activation of various signaling pathways (Brizzi et al., 2012).
During the main process of tumor carcinogenesis, the expression of integrins
significantly changes, and different types of tumors show distinct integrin
expression profiles (Rabinovitz et al., 1996; Bertotti et al., 2002). Importantly,
integrins can directly promote cell adhesion by serving as ligands of the
extracellular matrix, or indirectly activate growth factors and intracellular
signaling pathways to regulate extracellular matrix remodeling. For instance,
integrins interact with receptor tyrosine kinases (RTKs) on cell surface and
activate cellular signaling pathways that are critical for tumor metastasis (Baass
et al., 1995). In particular, integrin α6β4, which associates with the epidermal
growth factor receptor (EGFR), is abundant in pancreatic carcinoma. Integrin
αVβ3 in cooperation with the EGFR and the platelet-derived growth factor
(PDGF) dominates in glioblastomas and melanomas (Hammond, 2001; Recio et
al., 2002). Furthermore, most integrins activate focal adhesion kinase (FAK),
which causes the phosphorylation of downstream signaling protein (Yang et al.,
2011; Reilly et al., 2001). Taken together, the crosstalk between integrins and
cell surface receptors is important for the transduction of inter- and extracellular
signals.
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1.3.2 Proteases influence extracellular matrix remodeling
A balance between cells and surrounding extracellular matrix is crucial for
promoting cell development. However, during cancer progression, this balance
is broken mainly due to the remodeling of the ECM by proteases secreted by
tumor cells (Samnegard et al., 2005). Proteases are molecules of relatively small
size and are compact, spherical structures that can catalyze the cleavage of
peptide bonds or hydrolyze large proteins to smaller molecules (Apte et al.,
2004; Fayard et al., 2009). To date, proteases are broadly identified as
metalloproteases, serine proteases, threonine proteases, cysteine proteases and
glutamic acid proteases.
Cleavage and degradation of extracellular matrix components by different
families of proteases are the main processes during extracellular matrix
remodeling and are important for regulating extracellular matrix abundance and
structure (Fayard et al., 2009), as well as for releasing biologically active
molecules, such as growth factors (Colige et al., 2005). During metastatic
dissemination, two essential families of proteases, metalloproteinases and serine
proteases, are the main enzymes involved in extracellular matrix remodeling.
1.3.2.1 Metalloproteinase
Matrix metalloproteinases (MMPs)
The family of metalloproteinases contains matrix metalloproteinases (MMPs)
and adamalysins (ADAMs). MMPs, a family of zinc-dependent endopeptidases,
are the main enzymes involved in extracellular matrix degradation. MMPs were
originally categorized based on their specificity for extracellular matrix
components, including gelatinase A (MMP-2), gelatinase B (MMP-9),
stromelysins, collagenases and matrilysin. However, as a growing list of MMP
substrates have been identified. MMPs are currently divided into secreted
MMPs (Escrevente et al., 2011) and membrane-type MMPs (MT-MMPs)
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(Hakulinen et al., 2008). According to the structural blueprint of MMPs, most
MMPs display three domains, including the propeptide (Fayard et al., 2009;
Ngora et al., 2012), a catalytic domain, as well as the hemopexin-like C-terminal
domain that is linked to the catalytic domain. Interestingly, the activity of MMPs
is low in normal conditions but increase during repair or remodeling processes
as well as in pathological or inflammatory tissue (Sanderson et al., 2005). In fact,
all the MMPs are synthesized and secreted in the latent form. They are activated
by sequential proteolysis of the propeptide that binds and blocks the active site
cleft (Yu et al., 2012; Samnegard et al., 2005).
Adamalysins
The adamalysin family includes ADAMs, which is a disintegrin and
metalloproteinases, and ADAMTS, the ADAMs contain a thrombospondin
motif. ADAMs contains a disintegrin and a metalloproteinase domain, whereas
ADAMTS are ADAM proteases with a thrombospondin motif (Colige et al.,
2005; Apte et al., 2004). Although all ADAMs contain a metalloproteinase
domain, only less than half of them show proteolytic activity. ADAMs are
membrane-bound enzymes which can cleave transmembrane protein
ectodomains adjacent to the cell surface, thereby releasing the complete
ectodomain of cytokines, adhesion molecules, receptors, and growth factors
(Escrevente et al., 2011).
Clinically, the adamalysin family is implicated in various pathological events
including tumor metastasis and fibrosis through shedding of growth factors,
cytokines and apoptosis-inducing ligands (Fayard et al., 2009; Ngora et al.,
2012).
Metalloproteinase inhibitors
Since there is a clear connection between extracellular matrix degradation
through proteases and tumor invasion, numerous studies have linked inhibition
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of proteases by synthetic inhibitors with a corresponding suppression of tumor
metastasis. Furthermore, the tissue inhibitors of metalloproteinases (eg., TIMPs)
are natural metalloproteinases inhibitors and commonly expressed at tumor sites.
They are the most essential physiological inhibitors of metalloproteinases
(Kawaguchi et al., 1997). The TIMP family is comprised of four members
(TIMP1 to TIMP4), which form 1:1 stoichiometric complexes with active
MMPs, ADAMs and ADAMTS, leading to the inhibition of their proteolytic
activity.
In the cancer microenvironment, different sets of metalloproteinases and TIMPs
are mostly generated by tumor and non-transform cells (Zoller 2009), and
released into the outside extracellular space, where they regulate the matrix
around tumor cells (Khokha, 1994; Kawaguchi et al., 1997). The function of
proteases in tumor progression depends on a delicate local balance between
metalloproteinases and their physiological inhibitors (Fayard et al., 2009). Thus,
during the invasive process, TIMPs are presented primarily by the cancer cells
and serve as a regulatory mechanism for controlling the activity of the MMPs.
1.3.2.2 Serine proteases
The serine protease family occupied above one-third of all the identified
proteases. Their distinctive feature is the nucleophilic serine in their active site
(Kriegbaum et al., 2011). The urokinase plasminogen activator (uPA) is the
most essential serine protease, and has been recognized as a prognostic marker
in many human malignancies. uPA always interacts with its receptor uPAR
(CD87) on the cell surface, and facilitates tumor cell motility and extravasation
via regulating local proteolysis and these separating cells from the extracellular
matrix components (Xu et al., 2010; Kawaguchi et al., 1997).
The inhibitors interaction like uPA/uPAR are important suppressors for tumor
cell invasion, angiogenesis and metastasis. Plasminogen activator inhibitor-1
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(PAI-1), which located in the uPA/uPAR system is able to prevent the cleavage
of plasminogen as well as excludes plasmin from their surrounding
microenvironment.
1.3.2.3 Proteases affect extracellular matrix modulation and
tumorigenesis
During the first step of tumor migration and invasion, cancer cells require to
detach from adjacent cells and surrounding matrix through the cleavage by
protease (Kessenbrock et al., 2010). In this process, the extracellular matrix is
remodeled and components of the extracellular matrix are degraded by the
proteases to facilitate cancer progression. For instance, cleavage of laminin-5 γ2
chains by MMP-2 and MMP-14 produces a fragment containing epidermal
growth factor (EGF)-like motifs that engages EGFR (EGF receptor) and integrin
signaling on cell surface, leading to cell migration (Hakulinen et al., 2008;
Ngora et al., 2012). Several types of the collagen family including collagen III,
IV, IX and X, as well as elastin, and fibronectin are degraded by MMP-3. This
matrix protein degradation affects cell adhesion and migration (Samnegard et al.,
2005). Furthermore, the various interactions between MMPs promote focal
degradation of the extracellular matrix during invasion. (John et al., 2001;
Egeblad et al., 2002).
Beyond the cleavage of extracellular matrix components, proteases also take an
important part in interfering with the interaction during tumor cell of
progression (Figure 2). For example, E-cadherin is a critical molecule for cell-
to-cell adhesion. The deregulation of E-cadherin by MMP-3 and MMP-7 can
induce epithelial-mesenchymal transition (EMT), thereby promote tumor
metastasis. In addition, MMP-14 can degrade the tyrosine-protein kinase-like 7
(PTK7), a key inhibitor of tumor invasion, which leads to cancer cell motility
(Castells et al., 2012). CD44, a main surface receptor for hyaluronic acid (HA),
is cleaved by MMP-9 and MMP-14. Studies showed that the disruption of the
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CD44-MMP-9 complex at the cell surface through overexpression of the CD44
extracellular domain could inhibit tumor migration and invasion (Zöller, 2011).
Besides being involved in cell adhesion and motility, emerging evidences
indicate that proteases are engaged in the formation of a metastatic niche (van
Hinsbergh et al., 2008; Yu et al., 2000). As mentioned, the formation of a
premetastatic niche mainly requires soluble factors (e.g. VEGF) secreted by
primary tumor cells and the fibronectin that accumulates at surrounding stroma
cells. MMP-2 and MMP-9 take important roles on releasing and activating the
Kit ligand, and other molecules like vascular endothelial growth factor, which
are involved in creating a tumor metastasis supporting microenvironment
(Figure 2). Furthermore, MMPs also display multiple functions during tumor
angiogenesis (John et al., 2001). Taken together, several genes or matrix
proteins are regulated by proteases that trigger extracellular matrix remodeling
and thereby the switch towards metastasis and neovascularization at distant sites.
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Figure 2. Functions of MMPs in the tumor microenvironment. Proteinases and their substrates in each
of the tumor progression steps are as follows, 1) Tissue invasion and cancer cell intravasation. 2)
Highly vascularized tissues and new blood vessel generation (angiogenesis). 3) Recruitment of
inflammatory cells to the tumor microenvironment; 4) Metastatic niche formation. MMP-2, MMP3
and MMP-9 are involved in this process by releasing factors from the bone marrow (BM).
(Kessenbrock et al., 2010)
1.4 Role of CD44 in tumor metastasis
1.4.1 Structure and expression of CD44
The glycoprotein CD44 is encoded by a single gene, however the corresponding
mRNA is composed of 20 exons (Bennett et al., 1992; Arch et al., 1992). As
shown in figure 3, the first, as well as the last five (exon 1-5 or exon 6- 20)
exons are all constant exons, whereas the intermediate No. 6-15 exons are
combinations due to alternative splicing of the CD44 pre-mRNA. Exons 6-15
combination leads to the generation of many variable regions and different
isoforms, which named as CD44 variant v1-v10 (Banerji et al., 1998).
Up to now, at least 20 different isoforms of CD44, with a molecular weight of
85-230 kDa, have been identified in many cell types (Günthert et al., 1997). The
smallest CD44 molecule (85-95 kDa) is the standard isoform (CD44s), which
does not harbor any variant exon and is ubiquitously expressed in vertebrate
cells. The extracellular domain of CD44 contains a hyaluronic acid (HA) and
other glycosaminoglycan (GAG) binding sites (Zöller, 2011; Christ et al., 2002).
The cytoplasmic domain could be encoded by exons 9 or 10, which is essential
in cell migration as well as cellular signal transduction via binding cellular
molecules (Hyman et al.,1998; Günthert et al., 1997).
CD44 variants are closely related with tumor progression. For instance,
expression of variant isoforms including CD44v6 correlates with poor prognosis
in many cancer types such as cervical cancer, colorectal carcinoma (Kuhn et al.,
2007; Berg et al., 2012), acute myeloid leukemia (Legras et al., 1995; Hirata et
al., 1998), and pancreatic carcinoma (Marhaba et al., 2004; Megaptche et al.,
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2010). Moreover, high expression of CD44v6 correlates with lymph node
metastasis formation (Kunishi et al., 1997; Wang et al., 2013).
Figure 3. The CD44 gene molecule and CD44 protein structure is shown. a) Exons of CD44. b)
Examples of alternatively spliced CD44 proteins. c) The CD44 molecule comprises many
extracellular domains, a stalk-like region close to the transmembrane region where the variant exons
products can be inserted. There are multiple sites for N- and O-glycosylation and two active
glycosaminoglycan (GAG) binding sites (Zöller, 2011).
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In a clinical study, it has been indicated that CD44v5, CD44v6, and CD44v7 are
present in non-small cell lung carcinomas (NSCLCs), whereas there is low
expression level of these variants v5 to v7 in lung tissues (Legras et al., 1995;
Miyoshi et al., 1997). Another case of in vivo experiments showed lung
metastasis formation of breast cancer cells occurred after orthotopic
transplantation of CD44 variant-expressing breast cancer cells 4T1 (Yae et al.,
2012). However, the high expression of CD44 isoforms does not always have a
positive correlation with tumor metastasis. For instance, in oral squamous cell
carcinomas, the low expression of CD44v6 promotes lymph node metastasis
formation (Kunishi et al., 1997). Overall, the physiologic and pathologic
behavior of various cell types is associated with different expression of CD44
variant isoforms.
1.4.2 CD44 associated molecules in cancer
CD44 also serves as receptors for many extracellular matrix components such as
laminins, fibronectin, and other ligands (Bourguignon et al., 2002). Hyaluronic
acid (HA) is the well-known ligand for both CD44s and CD44 variants. The
interaction between CD44 and HA is characterized as a principal mediator of
cell proliferation in breast carcinoma, glioma and malignant mesothelioma
(Bloor et al., 2001, Tienthai et al., 2007).
CD44 could act as a important co-receptor for receptor tyrosine kinases system
(RTKs). CD44 influence the activation of RTKs such as the hepatocyte growth
factor receptor (HGFR/c-Met). In fact, the variant isoform CD44v6 plays a
prominent role as a co-receptor for RTKs (Orian-Rousseau et al., 2002). The
activation of c-Met through theCD44v6 bind its ligand, like hepatocyte growth
factor (Tremmel et al., 2009).
Beyond this, CD44 also interacts with MMPs and it serves as an important
platform where MMPs can associate with their substrates, which contributes to
cancer progression. For instance, the activation of transforming growth factors-β
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(TGF-β) is strongly dependent on MMP-9 binding to the cell surface via
CD44v6 (Schmidt et al., 2004; Yu & Stamenkovic, 2000). The recruitment of
MMP-9 to the cell surface supported by CD44 not only contributes to matrix
proteins degradation, but also causes the proteolytic activation of the TGF-β
precursor to induce tumor angiogenesis and metastasis (Ge et al., 2012).
1.4.3 CD44 is involved in extracellular matrix assembly
CD44 serves as a transmembrane receptor of hyaluronic acid, thus the
interaction of CD44-HA does not only promote tumor cell arrest and
extravasation (Yae et al., 2012), but also modify the surrounding matrix to
support cell colonization.(Yae et al., 2012). For instance, tumor cells support the
increase of hyaluronic acid expression that facilitate the formation of the pre-
metastatic niche (Hirata et al., 1998; Bourguignon et al., 2000).
Some previous researches provide some evidences that CD44 is directly
involved in extracellular matrix (Bennett et al., 1995; Jung et al., 2009;
Bourguignon et al., 2012)remodeling and cancer progression. Klingbeil et al.
established CD44v4-v7 (CD44v) stable knockdown cell lines from a highly
metastatic tumor line (Klingbeil et al., 2009). These stable knockdown cell lines
showed a significant reduction in metastatic capacity, which was mostly due to
an altered tumor extracellular matrix (Jung et al., 2009). This altered matrix
secrete by CD44v knockdown tumor cells does not support adhesion of neither
CD44v knockdown nor wildtype cell lines. CD44v4-v7 associates with matrix
proteins to regulate cell adhesion and to form a supporting microenvironment
for the pre-metastatic niche might be in a CD44v6-dependent manner (Jung et
al., 2012). In fact, the absence of CD44v is accompanied by a strikingly reduced
expression of hyaluronan synthases type 3 (Jung et al., 2009; Jung et al., 2012).
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1.5 Exosomes
Exosomes are endocytic origin, small (30-100nm) vesicles that are released
from various cell types in vitro and in vivo (Lakkaraju et al., 2008, Peinado et
al., 2012). Exosomes are derived from multivesicular bodies (MVB), which
either fuse with lysosomes or fuse with the plasma membrane (PM) and secrete
intraluminal vesicles (ILVs). Thus, exosomes have similar biochemical
characteristics to the internal vesicles of MVB (Théry et al., 2002, Zöller, 2009).
Notably, exosomes contain many lipids (Mittelbrunn et al., 2011; Zöller, 2009),
proteins, mRNA and miRNA (Alderton et al., 2012; Théry et al., 2002), these
components which are crucial in intercellular communication.
1.5.1 Exosome generation
The generation of exosomes starts with the endocytosis of membrane domains
from the cell surface, with the endocytosed membrane being called early
endosomes. The early endosome formation occurs either in a clathrin-dependent,
or in a clathrin-independent manner, which is generated by lipid-rafts. The
formation of MVB is initiated in the late endosomes through sorting of ILVs via
inward budding of limiting membranes (Alderton et al., 2012; Théry et al.,
2002). As figure 4 shows, MVBs can be processed via two routes. MVBs either
traffic to lysosomes, leading to the degradation in the proteasome, which are
named degradative MVBs, or fuse with the plasma membrane and release their
cargo ILVs into the extracellular space, which are named exocytic MVBs, and
the released ILVs are named exosomes (Mittelbrunn et al., 2011; Zöller, 2009).
Inward budding and subsequent fission of early endosomes and their transport to
MVBs requires several groups of complexes (Bache et al., 2003). In general,
ESCRTs are involved in the mechanisms governing the degradation of MVBs in
an ubiquitinylation-dependent manner (Hegmans et al., 2008). The ESCRT are
composed of four different protein complexes (ESCRT 0-III), which are
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essential for ILV construction. The ESCRT-0 complexes recognize and recruit
ubiquitylated proteins onto the endosomal membrane that initiates MVB
biogenesis. ESCRT-I and ESCRT-II complexes serve for membrane
deformation into buds with sequestered proteins, and the ESCRT-III protein
complex could subsequently drive vesicle scission (Sheldon et al., 2010; Niel et
al., 2011).
However, it has been suggested that MVBs and ILVs can also be formed
through ESCRT-independent (ubiquitinylation-independent) pathways. Indeed,
the MVBs synthesis is not abolished in the absence of ESCRT. Cells can employ
another alternative manner to sorting proteins into MVB, which is regulated by
lipid membrane constituents of the MVB. In this sorting mechanism, the
proteins are assigned into the ILVs based on their intrinsic physical properties,
and then segregated into raft-like microdomains (de Gassart et al., 2003).
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Figure 4. Exosome composition and generation. a) and b) Exosomes are derived from multivesicular
bodies (MVB), the fusion of MVB with the plasma membrane (PM) and then secrete the intraluminal
vesicles. c) The common components of exosomes. d) Exosomes uptake follows several routes such as
specific receptors binding, phosphatidylserine receptor binding, or fusion with the target cell
membrane. EE: early endosome; TEM: tetraspanin-enriched microdomain. (Zöller, 2009)
1.5.2 Exosome composition
The component of exosomes can be identified by various techniques including
western blotting (WB), enzyme linked immunosorbent assay (ELISA), flow
cytometry, and genomic technologies such as miRNA or mRNA microarrays.
Analysis of exosomes by different technologies expands our insight into the
exosome-microenvironment crosstalk.
As Figure 4c shows, exosomes carry a large number of common proteins,
mRNA and miRNA (Zöller, 2009). One major class of exosome cargo proteins
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is adhesion molecules. These proteins include integrins, CD146, CD18, CD11a,
CD11-b, CD11-c and milk-fat-globule EGF-factor VIII (MFG-E8) (Théry, 2011;
Mittelbrunn et al., 2011; Valadi et al., 2007). Another widely identified protein
group is tetraspanins, a family of transmembrane proteins abundantly expressed
on the exosome surface. Tetraspanins, such as Tspan8 (Nazarenko et al., 2010),
CD9 (Murayama et al, 2008), CD81, CD63 (Berditchevski et al, 2007) and
CD151 (Yue et al, 2013), modulate biological functions via tetraspanin-enriched
microdomains (TEMs) that are critical in tumor metastasis and angiogenesis
(Rana et al. 2011; Wang et al. 2012). In addition, exosomes are also rich in
metabolic enzymes, heat-shock proteins, tubulin, proteases, antigen presentation
proteins like the major histocompatibility complex (MHC) class I and II, signal
transduction molecules, and the lysosomal-associated membrane proteins,
LAMP1 and LAMP2 (Thery et al., 2001; Silverman et al., 2010; Simons &
Raposo et al., 2009; Hegmans et al., 2004). Notably, tumor derived exosomes
contain large numbers of tumor specific proteins, mRNA and miRNA, and
thereby transfer these cargoes to their target cells. These tumor exosomal
molecules such as cadherin-17, Tspan8 and epithelial cell adhesion molecule
(EpCAM) are tumor cell-specific, which can be clinically used as diagnostic
markers (Zöller, 2009).
1.5.3 Target modulation by exosomes
The extracellular or intercellular communication between tumor and stroma
cells was for a long time considered to require cell-cell or cell-ECM interactions
to regulate cancer progression. It is well accepted that exosomes fulfill at least
part of these activities. Thus, despite serving as potential diagnostic marker
(Zöller, 2013; Madhavan et al., 2015), exosomes are also recognized as critical
mediators of the intercellular crosstalk with the tumor microenvironment.
Exosomes can transfer messages to target sites in the microenvironment
basically through three manners (Figure 4d). First, exosomal membrane proteins
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can bind to the surface of target cells, acting as ligands for receptors (e.g.
phosphatidylserine receptors), thereby activating or regulating intracellular
signaling. Second, exosomes, can fuse with the membrane of target cells so that
exosomal membrane proteins and lipids become integrated into the host cell
membrane and modify the plasma membrane through the addition of new
membrane receptors and different lipid components. Third, liberation of the
exosome contents after uptake can strongly affect the targets and lead to target
cells reprogramming. Thus exosomes can modulate target cell composition as
well as activate signaling pathways to regulate physiological and pathological
processes ( Stoeck et al., 2006; Simons & Raposo et al., 2009).
The tumor cell derived exosomes contribute to tumor metastasis through
modulating their targets and breaking anti-tumor immune reactions (Ge et al.,
2012). These processes depend on activation of ligands, as well as extracellular
matrix degradation by exosomal proteases (Egeblad et al., 2002). Furthermore,
tumor exosomes also release many regulators of proteases, which enhance the
activity of proteases and thereby stimulate the pro-invasive factors (e.g. HGF) in
recipient cells (Cho et al., 2012).
It is also well known that tumor cells create their own matrix and further affect
host cells to generate a microenvironment that support tumor cells survival and
motility (Garnier et al., 2010; Jung et al., 2009), but how tumor exosomes
participate and influence this progress is still poorly understood. Interestingly,
current studies indicate that the interaction between exosomal proteases and
target cells also requires the cooperation with CD44 (Simpsonet al., 2009; Stoeck
et al., 2006). Since CD44 is abundantly expressed in exosomes secreted by
many types of cancer cells, and is an essential receptor for matrix protein,
understanding how the interaction between exosomal proteases and CD44
contributes to targets modulation becomes essential and important.
1.6 The BSp73 tumor model
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The BSp73 tumor is a pancreatic adenocarcinoma that spontaneously arose in
the BDX rat strain (Matzku et al., 1983). The primary BSp73 tumor harbors two
different sublines, with a local tumor in the pancreatic organ and an ascitic
metastasic tumor. The subcutaneously implanted local tumor maintained local
growth and generated a solid tumor at the implantation site (AS cell line),
whereas tumor cells derived from the ascites, instead of locally growing, rapidly
spread via the lymphatic system to the lung, where they form excessive miliary
metastases (ASML cell line). The highly metastatic variant ASML has a
spherical-like morphology, while the non-metastatic variant AS shows fibroid
tube morphology. To further characterize the different metastatic properties
between AS and ASML, monoclonal antibodies were generated and selected for
specific binding to the metastasizing ASML (Seiter et al., 1993; Matzku et al.,
1989). Through these studies, many proteins were identified as metastasis-
supporting molecules. It is very interesting to find that, among them, CD44v6,
acting as a tumor invasion inducer in pancreatic cancer is the most prominent
one. Thus, the BSp73 tumor provides a good model to study the function of
CD44v6 in cancer metastasis.
1.7 Aim of the thesis
The essential hallmark of multicellular organisms is intercellular communication
that can be mediated by molecule transportation or direct cell-cell contact.
However, in the last decades, exosomes, particularly tumor-derived exosomes,
have been demonstrated as the third mechanism of intercellular communication.
Tumor exosomes can communicate with neighboring tumor cells, stroma cells,
hematopoietic cells as well as the host matrix.
To date, information has been collected mostly for the impact of tumor
exosomes on stroma and hematopoietic cells, whereas the communication with
the host matrix has been neglected. In my thesis, I focused on the latter point
and attempted to answer the following questions:
Introduction
21
1. Do tumor exosomes communicate with the host matrix and if yes, what are
the exosomal molecules that are engaged in this communication?
2. What are the consequences of the interaction between tumor exosomes and
the extracellular matrix components?
3. How do tumor exosome-induced alterations of the matrix cross talk with
stroma host cells?
4. What is the special role of exosomal CD44v6 in the communication between
exosomes and the host matrix?
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2. MATERIALS AND METHODS
2.1 Materials
2.1.1 Instruments
Name Company
Camera system Spot CCD Diagnostic Instruments, Sterling Heights,
Carl Zeiss LSM710 confocal Carl Zeiss, Hamburg, Germany
Charge-coupled device (CCD) Hamamatsu, Herrsching,Germany
Cell chamber Neubauer improved Brand, Wertheim
Centrifuge Sorvall RC5B Plus Kendro, USA
Centrifuge Biofuge fresco Heraeus, Hanau, Hanau
DNA-agarose gel electrophoresis Bio-Rad, Munich
FACS Calibur Becton-Dickinson, Heidelberg
Fuji Film Imaging Plate BAS-MS Fuji Photo Film, Düsseldorf
Hyper processor (for processing Amersham, Freiburg
Incubator for molecule biology Melag, Berlin
Incubator for cell culture Labotec, Goettingen
Master cycler (PCR cycler) Eppendorf, Hamburg,
Magnetic stirrer 3000 Heidolph, Keilheim
Microscope DMBRE Leica, Bensheim
Microwave Phillips, Wiesbaden
Photocassette Amersham, Freiburg
Ph-Meter-761 Calimatic Knick, Berlin
Photometer Ultraspec III Amersham, Freiburg
Pipettus-Akku Hirschmann, Eberstadt
Pipettes Eppendorf, Hamburg
Power supply PS 9009 GIBCO, Darmstadt
Rotor GSA Kendro, USA
Rotor SW34 Kendro, USA
Rotor SW41 Ti Beckman Coulter, Krefeld
Sterile hood Heraeus, Hanau
Sonicator Sonoplus Bandelin, Berlin
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Table top centrifuge Heraeus, Hanau
Thermo-mixer Eppendorf, Hamburg
Ultrasound homogenizer Bandelin Electronik
Water-bath Julabo, Seelbach
Weighing scale RC210 D Sartorius, Goettingen
Whirlmixer Vortumor exosome Si Inc., New York, USA
2.1.2 Miscellanoeus materials
Name Company
Cell culture flasks 25cm2, 75cm2 Greiner, Frickenhausen
Cell culture 96-well, 24-well, 6-well Greiner, Frickenhausen
Centrifugal concentrators Vivaspin Vivascience, Hannover
Cryovials Greiner, Frickenhausen
Coverglass R. Langenbrinck, Emmendingen
Dako pen DakoCytomat., Glostrup, Denmark
Falcon tubes 15ml, 50ml Greiner, Frickenhausen
Glass slides R. Langenbrinck, Emmendingen
Hyperfilm ECL Amersham, Freiburg
Needles BD Biosciences, Heidelberg,
Nitrocellulose membrane Hybond Amersham, Freiburg
Parafilm Greiner, Frickenhausen
Petridishes Greiner, Frickenhausen
Pipette tips Sarstedt, Numbrecht
Sterile filter 0,2μm Renner, Darmstadt
Syringes BD Biosciences, Heidelberg
Transwell migration (Boyden) Neuroprobe, New York, USA
WhatmanTM 3MM paper Scleicher & Schüll, Dassel
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2.1.3 Chemicals and reagents
Name Company
Acetic acid Riedel-de Haen, Seelze
Acetone Fluka, Buchs, Switzerland
Agarose Sigma, Steinheim
Ammonium persulphate (APS) GIBCO, Darmstadt
Bio-Rad, Munich Bradford reagent Bio-Rad, Munich
Bovine Serum Albumin (BSA) PAA, Pasching, Austria
Brij 96 Fluka, Buchs, Switzerland
Calcium chloride Merck, Darmstadt
Chloroform Riedel-de Haen, Seelze
Carboxyfluorescein-succinimidylester Invitrogen, Darmstadt
cis-Diaminplatinum(II)dichlorid Sigma-Aldrich, München
Crystal violet Sigma, Steinheim
Dimethyl formamide Merck, Darmstadt
Dimethyl sulfoxide (DMSO) Merck, Darmstadt
Ethanol Riedel-de Haen, Seelze
Ethidium bromide Merck, Darmstadt
Ethylenediamine tetraacitic acid (EDTA) Sigma, Steinheim
Foetal Calf Serum (FCS) PAA, Pasching, Austria
Formaldehyde (37%) Merck, Darmstadt
G418 sulphate PAA, Pasching, Austria
Gelatine (cold water fish skin) Merck, Darmstadt
Glucose Merck, Darmstadt
L-Glutamine AppliChem, Darmstadt
Glycerine Roth, Karlsruhe
Glycine GERBU, Gaiberg
HEPES GERBU, Gaiberg
HiPerfect-Reagent for transfection Quiagen, Hilden
Hydrochloric acid (HCl) Riedel-de Haen, Seelze
Hygromycin PAA, Pasching, Austria
Materials and methods
25
Immersion oil Zeiss, Goettingen
Magnesium carbonate Merck, Darmstadt
Magnesium chloride Merck, Darmstadt
Magnesium sulphate Merck, Darmstadt
Milk powder Roth, Karlsruhe
Methanol Riedel-de Haen, Seelze
N,N,N´N´-Tetramethylenediamine Sigma, Steinheim
Paraformaldehyde Sigma, Steinheim
Penicillin Sigma, Steinheim
Phenylmethylsulphonylfluoride (PMSF) Sigma, Steinheim
PMA Sigma, Munich, Germany
Potassium chloride Merck, Darmstadt
Potassium dihydrogenphosphate Merck, Darmstadt
Potassium tetrathionate Merck, Darmstadt
Protease Inhibitor Cocktail Tablets Roche Diagnostics, Mannheim
Protein G Sepharose 4 Fast Flow Amersham Biosciences, Freiburg
RPMI 1640 GIBCO, Darmstadt cell culture
Sodium acetate Merck, Darmstadt
Sodium azide AppliChem, Darmstadt
Sodium carbonate AppliChem, Darmstadt
Sodium chloride Fluka, Buchs, Switzerland
Sodium hydrogen phosphate Merck, Darmstadt
Sodium dodecyl sulphate (SDS) GERBU, Gaiberg
Sodium hydrogen carbonate AppliChem, Darmstadt
SP-Dio18(3) dye for exosome labeling Invitrogen, Darmstadt
Tris Roth, Karlsruhe
Triton-X-100, Triton-X-114 Sigma, Steinheim
Trypan bue Serva, Heidelberg
Trypsin Sigma, Steinheim
Tween 20 Serva, Heidelberg
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2.1.4 Buffers and solutions
Bicarbonate buffer 15mM Na2CO3, 35mM NaHCO3, pH 9.6
Blot buffer 25 mM Tris, 192mM Glycine,0.1% SDS, 20%
Methanol
Ethidium Bromide 0.01% (w/v) in water. Store in dark.
Freezing medium 10% DMSO in FCS
HEPES buffer 25mM HEPES, 150 mM NaCl, 5mM MgCl2, 1 mM
PMSF, Protease inhibitors
6x Laemmli-buffer 350mM Tris, pH6.8, 10% (w/v) SDS, 36% (w/v)
Glycerine, 0.01% (w/v) Bromophenol blue
LB medium 10g peptone, 5g yeast extract, 10g NaCl. Make
volume to 1l. Add 15g agar for LB plates
Running buffer for
SDS-PAGE (10X)
1%SDS (w/v), 144g Glycine, 30g Tris. Make volume
to 1l with bidestilled water
PBS 137 mM NaCl, 8.1mM Na2HPO4, 2.7 mM KCl,
1.5mM KH2PO4, pH 7.4
Stripping buffer 62.5 mM Tris-HCl (pH 6.8), 2% SDS ,0.1 M, 2-
Mercaptoethanol
TAE buffer 242g Tris base, 57.1ml Glacial acetic acid, 100ml
0.5M EDTA pH 8.0. Make volume to 1l and adjust
pH to 8.5
TEN buffer 40mM Tris/Cl pH 7.5, 1 mM EDTA pH 8.0, 150
mMNaCl
2.1.5 Kits
Name Company
Quiaquick gel extraction kit QUIAGEN, Hilden, G.
Quiaquik Midiprep kit QUIAGEN, Hilden, G.
ECL Western Blotting Detecting Amersham, Freiburg, G.
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2.1.6 Markers
Name Company
GeneRulerTM 100bp and 1Kb DNA-
Ladder Plus
MBI Fermentas, St. Leon-Rot
PagerulerTM Prestained Protein Ladder MBI Fermentas, St. Leon-Rot
2.1.7 Antibodies
2.1.7.1 Primary antibodies
Antibody Supplier
α6β4 (clone B5.5) Matzku et al., 1989
actin BD, Heidelberg, G.
ADAM10 Santa Cruz, Heidelberg, G.
ADAM17 Santa Cruz, Heidelberg, G.
ADAMTS1 Santa Cruz, Heidelberg, G.
ADAMTS5 Santa Cruz, Heidelberg, G.
ADAMTS8 Santa Cruz, Heidelberg, G.
bFGF Oncogene, Boston, USA
CD9 (clone B2C11) BD Biosciences, Heidelberg;
Developmental studies Hybridoma bank
CD11a BD, Heidelberg, G.
CD11b (clone Ox42) European Association of Animal Cell
Cultures
CD11c (clone Ox41) European Association of Animal Cell
Cultures
CD13 Chang et al, 2005
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Antibody Supplier
CD18 BD Biosciences, Heidelberg, G.
CD29; (clone FW4.10.1) BD Biosciences, Heidelberg,
Developmental studies Hybridoma bank
CD44s (clone Ox50) European Association of Animal Cell
Cultures
CD44v6 (clone A2.6) Matzku et al., 1989
CD49c (clone Ralph3.1) BD Biosciences, Heidelberg,
Developmental studies Hybridoma bank
CD49b BD Biosciences, Heidelberg, G.
CD49c BD Biosciences, Heidelberg, G.
CD54 BD Biosciences, Heidelberg, G.
CD104 BD Biosciences, Heidelberg, G.
CD151 Claas et al., 2005
CD106 Biozol, Eching, G.
CD151 Matzku et al., 1998
claudin-6 Santa Cruz, Heidelberg, G.
collagen I Rockland, Gilbertsville, USA.
collagen II LabVision, Frem., CA, USA.
collagen III ARB, Golden, CO, USA.
collagen IV Rockland, Gilbertsville, USA.
CXCR4 Santa Cruz, Heidelberg, G.
D6.1A (clone D6.1) Matzku et al., 1998
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Antibody Supplier
EpCAM (clone D5.7) Matzku et al., 1998
EGFR Santa Cruz, Heidelberg, G.
ERK1/2 BD, Heidelberg, G.
FGFG BD, Heidelberg, G.
Fibronectin BD, Heidelberg, G.
HAdase Santa Cruz, Heidelberg, G.
Hyaluronan Rockland, Gilbertsville, USA.
HGF Santa Cruz, Heidelberg, G.
JNK BD, Heidelberg, G.
Jun BD, Heidelberg, G.
Laminin1 Rockland, Gilbertsville, USA.
Laminin5 BD, Heidelberg, G.
MMP2 Dianova, Hamburg, G.
MMP3 Santa Cruz, Heidelberg, G.
MMP9 Dianova, Hamburg, G.
MMP13 Dianova, Hamburg, G.
MMP14 Santa Cruz, Heidelberg, G.
Metallothio. Santa Cruz, Heidelberg, G.
Palladin Santa Cruz, Heidelberg, G.
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Antibody Supplier
PDGF BD, Heidelberg, G.
PDGFR BD, Heidelberg, G.
pJNK BD, Heidelberg, G.
pJun BD, Heidelberg, G.
pRas BD, Heidelberg, G.
Ras Santa Cruz, Heidelberg, G.
SDF1 Abcam, Cambridge, UK.
TF Santa Cruz, Heidelberg, G.
TGF Santa Cruz, Heidelberg, G.
Tenascin LabVision, Fremont, CA.
uPA Calbiochem, Darmstadt, G.
uPAR Calbiochem, Darmstadt, G.
VEGF Biotrend, Köln, G.
VEGFR1 Biotrend, Köln, G.
Vitronectin Biotrend, Köln, G.
vWF Abcam, Cambridge, UK.
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2.1.7.2 Secondary antibodies
Antibody Company
anti-mouse IgG-APC BD, Heidelberg, Germany
anti-mouse IgG-HRP Dianova, Hamburg, Germany
anti-mouse IgG-PE Dianova, Hamburg, Germany
anti-rabbit IgG-HRP Dianova, Hamburg, Germany
anti-hamster IgG Dianova, Hamburg, Germany
Streptavidin-HRP Sigma, Steinheim, Germany
2.1.8 Matrix proteins
Protein Supplier Concentration
Collagen I Sigma, Munich, G 10 μg/ml
Collagen II Sigma, Munich, G 10 μg/ml
Collagen IV Sigma, Munich, G. 10 μg/ml
Hyaluronan Sigma, Munich, G.
Fibronectin Sigma, Munich, G. 2 μg/ml
rat LN111 Sigma, Munich, G. 2 μg/ml
rat LN332
(LN5)
804G exosome-depleted culture
supernatant w/o FCS
50 μg/ml
Tenascin SKmel exosome-depleted
culture supernatant w/o FCS
50 μg/ml
Vitronectin Sigma, Munich, G. 2 μg/ml
Matrigel BD, Heidelberg, G. 4.5 mg/ml (1:1 dilution)
2.1.9 Inhibitors
Inhibitor Supplier Concentration
MMP9/ MMP13 inhibitor Merck, Darmstadt, G. 10 μg/ml
TIMP-2 inhibitor Merck, Darmstadt, G. 10 μg/ml
TAPI (TACE Inhibitor) Merck, Darmstadt, G. 10 μg/ml
2.1.10 Cell lines
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BSp73ASML (ASML-
wt)
metastatisizing rat pancreatic adenocarcinoma line
(Matzku et al., 1983)
BSp73ASMLCD44v4-
v7 knockdown
(ASML-CD44vkd)
Stable knockdown of CD44v4-v7 in ASML-wt cell
(Klingbeil et al., 2009)
804G rat bladder carcinoma line, LN5 secreting (Homma et
al., 1985)
Rat lymph node stroma
cells (Lnstr)
Isolated from rat lymph nodes (LeBedis et al., 2002)
Rat lung fibroblasts
(LuFb)
Isolated from lungs of BDX rats with NiSO4
Rat aorta endothelial
cells (RAEC)
Isolated from Wistar rats, Cell lining, Berlin
Lymph node cells
(LNC)
Isolated from lymph nodes of BDX rats
Bone marrow cells
(BMC)
Isolated from femur and tibia by flushing the bones
of BDX rats
2.1.11 Rat strain
BDX rats between 8-12 weeks were used for cell preparation and in vivo
experiments. The BDX rats were bred in the animal facility of the University of
Heidelberg (IBF), under pathogen-free conditions and provided steile food and
water ad libitum.
2.2 Methods
2.2.1 Cell biology
2.2.1.1 Cell culture
Cells were grown and maintained in RPMI 1640 medium containing 5%-10%
heat inactivated the FCS (also named as fetal calf serum) and antibiotics
(penicillin and streptomycin 100U/ml ). The cells were cultured in flasks or
plates at 37°C, 5% CO2 and 95% humidity. For passage, confluent cells were
detached by trypsin, EDTA or strong pipetting, and were divided into new flasks.
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Long term cell storage was performed by washing cells once with sterile PBS,
resuspending the cells in pre-cold FCS containing 10% DMSO. After step-
cooling, cells were kept in a -80°C freezer overnight and then vials were
transferred into liquid nitrogen.
For recovery, vials were put into a 37°C water bath, and instantly transferred
into pre-warmed medium, washed once at 4°C, 400rpm centrifugation to remove
the DMSO. The cell pellet was resuspended in fresh medium and cells were
transferred in culture flasks.
For functional experiments, the viability of cells was assessed by light
microscopy after trypan blue staining. Viability of over 95% was considered
sufficient.
2.2.1.2 Recloning of transfected cells through limiting dilution
To establish stable knockdown clones, the shRNA transfected cells were cloned
at 1-3 cells/well in F-bottom 96-well plates. Clones were evaluated by flow
cytometry, to select for clones with significant downregulation. However, the
shRNA transfected into tumor ASML cells were maintained in selection
medium containing 750 μg/ml geneticin (G418), and surviving cells were
regularly examined by Western blot or flow cytometry analysis for the selection
of stable knockdown clones.
2.2.1.3 Exosome preparation
Confluent cell cultures were cultured in serum free medium and supernatants
were collected after 48 to 72h of culture. Exosome isolation proceeded through a
series of centrifugation steps: 500g for 10min, 2000g for 10min, 5000g for 20
min, 10,000g for 30min. After this, exosomes were isolated by 2.5h of ultra-
centrifugation at 100,000g using a SW41Ti rotor in a Beckman Coulter
ultracentrifuge. The supernatant was collected as CM-exo.
Exosomes were further purified via a ucrose cushion centrifugation or a
discontinuous sucrose gradient centrifugation. Briefly, exosomes float at
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densities harbor from 1.15 to 1.19 g/ml on layer of sucrose gradients. The
exosome pellet was resupended in 800µl of buffer HEPES and totally mixed
with 80% sucrose, the mixture could be placed at the bottom of the 4ml
ultracentrifuge tube. Over this, 1.6ml of 30% sucrose in HEPES were carefully
layered, and followed by a next layer of 5% sucrose on top. The tubes were
carried to the SW41Ti rotor and centrifuged at 100,000g for 16h. Thereafter, 12
equal fractions were collected, the fractions 3 to 7 contain the purified exosomes.
For sucrose cushion, the exosome pellet generated by ultracentrifugation was
resupended in 20ml PBS, and the mixture of exosome-PBS was layered on 20ml
of 40% sucrose, and was ultracentrifuged at 100,000g for 90min. The top layer
was removed after centrifugation, and the lower sucrose layer, which contains
the exosomes was diluted with PBS and washed by ultracentrifugation (90 min,
100,000g). The method of sucrose cushion centrifugation was used for
separating dye-labeled exosomes from free-dye.
2.2.1.4 Fluorescent dye-labeling of ASML wt or kd exosomes
For exosmes labeling, 1mg of exosomes was labeled in 200μl of PBS containing
DHPE or SP-DioC18 (3) at 1:10,000 dilution in PBS for 25min. After this, the
labeled exosomes were washed twice and incubated with exosome-depleted FCS
in the dark for 30min so that the free dye binds to proteins in FCS. Dye-labeled
exosomes were centrifuged down after the wash with PBS. The labeled
exosome-pellets were purified by 40% sucrose cushion as described. The dye-
labeled exosomes were stored at -80˚C till further use.
2.2.1.5 Tumor/stroma matrix generation
Tumor ASML wildtype cells (ASML-wt) and ASML CD44v4-v7 knockdown
cells (ASML-CD44vkd), as well as rat lymph nodes stroma cells (Lnstr), lung
fibroblasts (LuFb) and aorta-derived endothelial cells (RAEC) were cultured as
described. The culture supernatants of tumor and stroma cells are referred as
tumor or stroma matrix, also named as conditioned medium (CM+exo). The
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CM+exo was further washed by centrifugation (90 min, 100,000g) to deplete
exosomes (CM-exo).
2.2.1.6 Adhesion assay
For measuring cell adhesion, F-bottom 96-well plates were pre-coated with
matrix proteins or cell culture conditional medium (CM-exo) at 4°C overnight,
and then blocked with 2% PBS/BSA. Adhesion of cells was checked by CFSE
fluorescence or by crystal-violet staining.
CFSE fluorescence assay was performed as follows: cells were labeled with
CFSE (5μM) for 25min in serum free medium until they obtained viewable
yellow color. 2x104 cells of these co-incubated w/wo exosomes were seeded on
pre-coated 96-well plates for 2 hours at 37°C. The plates were washed with PBS
and adhesion of cells was determined in a Fluoroskan Ascent multiplate reader
(excitation/emission: 490 nm/518 nm).
The crystal-violet staining assay was performed as follows: 2x104 cells co-
incubated w/wo exosomes were seeded on pre-coated 96-well plates for 2 hours
at 37°C. Cells were harshly washed by PBS twice, the adherent cells were fixed
by cold methanol and then stained with fresh 0.1% crystal violet solution for
30min. After staining, cells were dissolved in 10% acetic acid and staining
intensity was evaluated by a fluorescence ELISA reader (OD: 595 nm).
2.2.1.7 Migration assay
Cell migration was evaluated by wound healing, transwell migration
measurement and video microscopy. Firstly, the confluent monolayers were
cultured in a 24-well plate and scratched with a pipette tip. Wound healing was
observed by light microscopy after 12h-72h. Transwell migration was assessed
by the Boyden chamber assay. Cells (5x103) were seeded in the upper part of the
chamber in 40μl of RPMI/0.1% BSA. The lower part of the chamber, separated
by a 8-μm pore size polycarbonate membrane, contained 30μl of CM-exo w/wo
ASML or -CD44v knockdown exosomes (10μg/ml). Migrated stroma cells
Materials and methods
36
(Lnstr, LuFb and RAEC) were evaluated after 16 hours by staining the lower
surface of the membrane side with 0.1% crystal violet, measuring OD595 nm
after acetic acid lysis. Migration rate is presented as percentage of all input cells.
For video microscopy, cells were pre-treated w/wo different stroma CM-exo or
exosomes. Cell migrating routes were evaluated for 24 hours via an Olympus
IX81 inverse microscope, equipped with an incubation chamber (37°C, 5%CO2),
a charge-coupled device (CCD) camera and a ScanR acquisition software. The
photograph system took pictures every 20 minutes for each well and created
videos or albums of migrating cells. Migration routes were quantified according
to a software ImageJ, manual_tracking plugin (F.P. Cordeliére, Centre de
Recherche). The mean value of cell migration length per 1 hour is presented.
2.2.1.8 Invasion assay
For cell invasion, matrigel was thawed at 4˚C and diluted 1:1 with serum free
RPMI 1640 w/wo exosomes. 100μl of this mixture was seeded carefully into an
insert transwell chamber and incubated overnight at 37°C. The following day,
2x104 stroma cells (Lnstr, LuFb and RAEC) in serum free medium were layered
on the matrigel mixture and kept in a cell culture incubator for 24 hours. Cells
which stayed in culture medium or at the surface of the matrigel were removed,
and invading cells within the matrigel or penetrated through the transwell
chamber were documented by light microscope and were counted via ImageJ,
cell counting display.
2.2.1.9 Immunofluorescence
3x105 cells were seeded and grown on cover slides for 48h. Prior to staining,
cells were fixed, and then permeabilized with 0.2% of Tween in PBS and
1%BSA. Thereafter, cells were blocked with 0.2% gelatin (derived from
freshwater goldfish) for 15min and were incubated with primary antibodies (2-
10μg/ml) for 1h, 4˚C. Cells were incubated with fluorochrome-conjugated
secondary antibody. Finally, cover slides were washed and mounted in elvanol.
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Digitized images were generated by a Carl Zeiss LSM710 confocal microscope
and analyzed by software Carl Zeiss Axioview Rel. 4.6
2.2.1.10 Flow cytometry for cells and exosomes
The flow cytometry is a technique used to measure fluorescence labeling of
individual cells or exosomes. Cells (2x105 per sample), detached with trypsin or
EDTA, were seeded into U-bottom 96-well plates. Cells were incubated with the
primary antibody (1-5μg/ml). The fluorochrome-conjugated secondary antibody
(0.3-0.5μg/ml) was added and cells were incubated in the dark for 30min, at 4˚C.
For intracellular staining, cells were fixed in 1% formalin for 20min, and
permeabilized with 0.2% Tween in FACS buffer before incubation with the
primary and secondary antibodies. Samples were acquired and analyzed with the
FACS Calibur.
FACS was also used to characterize exosomes. Dye-labeled exosomes were
incubated with 4-μm aldehyde-sulfate latumor exosome beads. Where indicated,
latumor exosome beads (1μl) were coated with antibody or matrix proteins
(10μg/ml), blocking free aldehyde groups by incubating with 100mM glycine
for 20 min at room temperature before incubation with exosomes.
2.2.1.11 Apoptosis assay
For evaluating cell apoptosis, Lnstr, LuFb and RAEC (1x105) were co-cultured
with autologous CM-exo pretreated w/wo ASML-wt or -kd exo and were seeded
onto a 96-well plate in the presence of 5μg of cisplatin for 24h or 48h.
Thereafter, cells were washed with PBS/1% FCS. To monitor survival, cells
were incubated with Annexin-FITC/PI according to the manufacturer’s
conditions, afterthen, it could be evaluated by flow cytometry with two channels,
channel FL-1 for annexin-FITC, however, and channel FL-3 for PI.
2.2.1.12 Cell proliferation
Cells (3x103) pretreated with stroma CM-exo w/wo ASML or -CD44v
knockdown exosomes were seeded on F-bottom 96-well plates along with 3H-
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thymidine (10μCi/ml) and were cultured for 24 to 72h. The 3H-thymidine
incorporation was evaluated in a β-counter.
Alternatively, cells were labeled by CFSE and cell division was determined.
Briefly, stroma cells (3x103) were collected and washed twice by sterile PBS,
and were co-incubated with 5μM CFSE for 20min at 37˚C. The CFSE-labeled
cells were co-cultured with CM-exo pretreated with exosomes for 24h, 48h and
72h. Thereafter, dilution of the CFSE-labeled cells was evaluated by flow
cytometry.
2.2.2 Protein Biochemistry
2.2.2.1 Immunoprecipitation (IP)
Cells were lysed in lysis buffer (HEPES buffer containing 1% Brij96, protease
inhibitor cocktail) for 60min at 4°C with shaking. 1 mg of cell lysates or 100 µg
of exosomal lysates were immunoprecipitated with corresponding antibody
(2µg/ml or 200µl hybridoma supernatant) overnight at 4°C. Thereafter, samples
were precipitated with 5% ProteinG Sepharose for 1h at 4°C with rotation. The
complexes were washed three times with lysis buffer. All liquid was removed
through a 35g-needle attached to a vacuum pump to ensure minimal background.
Complexes were dissolved in Laemmli buffer, boiled at 95°C for 5min and
centrifuged shortly to separate sepharose beads from proteins.
2.2.2.2 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of
samples
(the SDS-PAGE running gel)
SDS-PAGE is a technique used to separate proteins according to their size. The
PAGE allows different size proteins to move at different rates. Two gel layers
were used to separate proteins, however the stacking gel (375mM Tris pH6.8,
0.1%SDS, also with 4% acrylamide-bisacrylamide, 0.1%TEMED (v/v), 0.1%
(w/v) APS allows them to enter the resolving gel. At the bottom, 5ml of
separating gel (375mM Tris pH8.8, 0.1%SDS, 10% acrylamide-bisacrylamide,
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0.1%TEMED (v/v), 0.1% (w/v) ammonium persulphate) allows the separation
of proteins. After complete polymerization, gels were loaded and run in SDS
running buffer at a constant voltage of 90V. Gels were either stained with
coomassie blue or subjected to Western blot analysis.
2.2.2.3 Western blotting
After SDS-PAGE, the gel was equilibrated for 10min in transfer buffer: This
transfer set was placed into an apparatus with black side facing black, and the
protein transfer was performed at 30V, overnight, at 4°C. After transfer had
been completed, the membrane was quickly checked with ponceau solution and
blocked with 5% (w/v) fat-free milk for 1h. The membrane was blotted with the
primary antibody, overnight at 4°C on a shaking platform. After three times
washing with PBST (PBS+ 0.1%Tween 20), the membrane was probed with
horse radish peroxidase (HRP)-conjugated secondary antibody (diluted 1:10000
in PBST) for 1h at room temperature, which was followed by additional three
washing steps. For biotinylated proteins, the membrane was detected with
Streptavidin-peroxidase. Detection was done by the Enhanced
Chemiluminescence system (ECL, Amersham Biosciences) and also these X-ray
films.
2.2.2.4 Zymography
Zymography is an electrophoretic technique for hydrolytic enzyme detection.
ASML and -CD44v knockdown CM-exo were collected from serum-free cell
cultures. The CM-exo and ASML and -CD44v knockdown exosomes (30μg
/sample) were mixed with Laemmli buffer and incubated for 15min at 37oC.
Samples were separated in a 10% acrylamide gel containing 1mg/ml gelatin.
Thereafter, the gelatin gel was washed three times by 2.5% Triton for 10min to
remove SDS, and was incubated in developing buffer (50mM Tris, 10mM CaCl2,
150mM NaCl, 2μM ZnCl2, pH 7.5) for 48h, 37oC. After 2 days, the gel was
stained with Coomassie-blue 250 and washed by destaining solution.
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2.2.2.5 Protease Activity
To investigate the protease activity of exosomes, 50μg ASML or -CD44v
knockdown exosomes were incubated with matrix proteins (1μg) or stroma CM-
exo (50μg) overnight, 37oC. The matrix protein degradation was evaluated by
SDS-PAGE gel running and Western blot (WB) or zymography.
For determining the protease inhibitor effect on indicated proteases, the ASML
and -CD44v knockdown exosomes were pre-treated with 10μg/ml inhibitor
(TAPI, TIMP-2 and MMP-9/13 inhibitor) for 5h, 37oC, and the altered
exosomes were co-incubated with matrix protein overnight as described. After
then, the matrix protein degradation was evaluated by WB.
2.2.3 Animal experiments
2.2.3.1 In vivo exosome targeting
Dye-labeled ASML and -CD44v knockdown exosomes (400 μg) were i.v.
injected into rats. BDX rats (three per group) were sacrificed after 48 hours and
various organs were excised and shock frozen in liquid nitrogen. Tissue sections
were counterstained by hematoxylin and eosin (H&E), and the recovery of
exosomes was detected by Zeiss confocal microscopy.
2.2.3.2 In vivo exosome modulation of ECM
Matrigel was mixed (1:1) with tumor exosomes (400 μg) in PBS and incubated
overnight at 37°C. The matrix-tumor exosome was subcutaneously (s.c.).
injected into BDX rats (five per group). The plug was removed after 5 days and
thereafter shock frozen. Plug sections were stained with the indicated primary
and secondary antibodies. After drying, samples were stained with H&E. The
sections of the exosome-modulated stroma matrix were evaluated by Zeiss
confocal microscopy.
2.2.4 Statistical analysis
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All assays were statistically evaluated, values represent the mean (±SD) of
triplicates and/or 3 repetitions. P-values<0.05 (Student’s t-test) were considered
statistically significant.
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3. RESULTS
There are emerging researches of the crosstalk between tumor exosomes and
host cells (e.g. stroma, endothelial and hematopoietic cells). However, the
impact of tumor exosomes on the extracellular matrix is largely unknown. As
extracellular matrix is an essential component of the organism, and contributes
to tumor cell expansion and spread, the first aim of my thesis was to clarify
whether and how tumor exosomes interact and influence host matrix.
3.1 Tumor derived exosomes bind to matrix proteins
To explore the hypothesis that tumor exosomes can influence host matrix,
exosomes from the highly metastatic rat pancreatic adenocarcinoma ASML and
the poorly metastatic ASML-CD44v4-v7 (ASML-CD44v) knockdown cells
were used. The ASML wild type exosomes and ASML-CD44v knockdown
exosomes were isolated by ultracentrifugation and further purified by a sucrose
gradient centrifugation.
3.1.1 Matrix proteins delivered by tumor and stroma cells
The conditioned medium (CM) from serum-free cell culture supernatant is
enriched in many different types of matrix proteins, which could be used as a
model of the extracellular matrix in vitro. To avoid interference of autologous
exosomes, the conditioned medium was depleted exosomes (CM-exo) by
ultracentrifugation.
My study started with characterizing matrix protein in ASML and ASML-
CD44v knockdown lines. As shown in figure 5A, collagen I, tenascin and
vitronectin were expressed at a similarly level in both cells, whereas the
expression level of collagen II, collagen IV, fibronectin and laminin111 in
ASML-CD44v knockdown cells was 40% less than in ASML cells.
The secreted matrix proteins also displayed distinct expression profiles in
ASML-wt and ASML-CD44v knockdown CM-exo. Despite the same expression
level of vitronectin and laminin332, secretion of these matrix proteins was
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significantly decreased in ASML-CD44v knockdown CM-exo compared to
ASML CM-exo. Furthermore, secreted collagen I, -IV and fibronectin in ASML
CM-exo were around five times more than in ASML-CD44v knockdown CM-exo.
Finally, collagen II was neither delivered by ASML or -CD44v knockdown cells.
Figure 5. Recovery of matrix proteins in tumor cells and CM-exo. (A, B) WB analysis of collagen I ,
collagen III, collagen IV and fibronectin , Tenascin, vitronectin (VN), laminin111 and laminin332
expression in ASML and ASML-CD44v knockdown cells (A) and CM−exo (B).
Lymph node stroma cells (LnStr), as well as lung fibroblasts (LuFb) are major
targets of ASML exosomes. Both stroma cells abundantly expressed matrix
proteins (Figure 6A), and the expression of secreted matrix proteins in CM-exo
showed only slight differences compared to the cellular expression. As shown in
figure 6, the expression of collagen I and II was higher in LnStr than LuFb cells
and CM-exo. However, collagen IV, which is enriched in LuFb CM-exo, was not
recovered in LnStr CM-exo. Other matrix molecules, including fibronectin,
vitronectin, tenascin and laminin were highly expressed in both stroma CM-exo.
With the above information, the stroma CM-exo as a host matrix model to verify
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and elucidate the interaction between tumor exosomes and extracellular matrix
components.
Figure 6. Recovery of matrix proteins in stroma cells and CM-exo. (A, B) WB analysis of collagen I
(coll I), collagen II (coll II), collagen IV (coll IV), fibronectin (FN), Tenascin, vitronectin (VN),
laminin111 (LN111) and laminin332 (LN332) expression in LnStr- and LuFb cells (A) and CM−exo (B).
3.1.2 Tumor exosomes bind to matrix proteins in vitro
To determine the binding of tumor exosomes to purified matrix proteins as well
as host matrix, ASML and ASML-CD44v knockdown exosomes were purified
as described and labeled with the fluorescent dye SP-Dio18(3). The latex beads
were coated with distinct matrix proteins overnight, and dye-labeled exosomes
were incubated with the matrix protein-coated beads for 2 h. The binding
capacity of tumor exosomes was evaluated by measuring the fluorescence
intensity of the labeled exosomes that bound to the beads. Flow cytometry
analysis revealed that ASML and ASML-CD44v knockdown exosomes showed
comparable binding capacities for laminin 111, laminin 332 and vitronectin.
However, ASML-CD44v knockdown exosomes strikingly lost binding capacity
for hyaluronic acid. ASML exosomes also exerted 20% stronger binding
Discussion
45
capacity for collagen I, -III, -IV and fibronectin than ASML-CD44v knockdown
exosomes (Figure 7A).
Tumor exosomes also bound to tumor and host matrix. CM-exo from ASML and -
CD44v knockdown lines, as well as LnStr-, LuFb- and rat aorta endothelial
(RAEC) lines were seeded on 96-well plates (F-bottom, ELISA plate) overnight
so that the components of matrix could attach to the plates. Dye-labeled ASML
or -CD44vkd exosomes were added and co-incubated with the matrix for 2h.
The binding of dye-labeled exosomes was analyzed by the fluorescence
microplate reader (Figure 7B). ASML exosomes strongly bind to ASML
autologous-, Lnstr-, LuFb- and RAEC CM-exo. Compared with ASML exosomes,
ASML-CD44v knockdown exosomes showed 30% less binding capacity for
Lnstr- and RAEC CM-exo, as well as 50% less binding capacity for ASML CM-
exo respectively. Importantly, ASML and -CD44v knockdown exosomes hardly
bound to ASML-CD44v knockdown CM-exo, which probably due to the reduced
level of matrix protein expression and distinct matrix organization in the
absence of CD44v6. To further confirm this finding, I seeded tumor and stroma
CM-exo onto glass cover-slides, and co-incubated the cover-slides with dye-
labeled ASML or -CD44v knockdown exosomes for 2h. The cover-slides were
observed by confocal microscopy. I found that tumor exosomes (red fluorescent
spots) could bind to LnStr-, LuFb-, RAEC- and ASML CM-exo, whereas the
binding of CD44v knockdown exosomes to matrix was much weaker.
Furthermore, Quantification of the exosome-covered area confirmed the
stronger binding capacity of ASML exosomes (Figure 7C).
Taken together, tumor exosomes can directly bind to matrix proteins and stroma
matrix in vitro. The binding capacity of ASML-CD44v knockdown exosomes
was significant reduced. In addition, the CD44v knockdown matrix possibly is
disorganized so that even ASML exosomes showed decreased binding.
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Figure 7. Tumor exosomes bind to matrix proteins in vitro. (A–C) ASML-wildtype (wt) and
ASML-CD44v knockdown (kd) exosomes were labeled with SP-Dio18, and free dye was removed by 2
times washing and ultracentrifugation. (A) Dye-labeled exosomes were co-incubated with matrix
protein–coated latex beads and then wash off to remove the un-bound exosomes, the matrix protein
Discussion
47
binding was measured by flow cytometry. (B) Tumor and stroma cell CM-exo were collected and
seeded. The co-incubation with dye-labeled exosomes for 2h. (C) Confocal microscopy was used to
evaluate the binding of exosomes to tumor or stroma CM-exo (scale bar, 10μm), and the exosome
covered area was quantified by imageJ. (A, B and C)
3.1.3 Adhesion molecule receptors are engaged in matrix protein binding
As the binding capacity of ASML wildtype and -CD44v knockdown exosomes
displayed significant differences, it became important to figure out the
contribution of exosomal adhesion molecules in matrix protein binding.
I first evaluated the adhesion molecule expression in ASML and -CD44v
knockdown exosomes by flow cytometry and WB. As shown in figure 8A, the
ASML exosomes expressed CD29, CD44 and CD104 (β4) at a significantly
higher level than ASML-CD44vkd exo, whereas expression levels of CD11b,
CD11c, CD18, CD49b, CD49c and CD54 were similar in both exosomes.
To determine whether highly expressed adhesion molecules in ASML exosomes
contribute to stronger matrix binding, dye-labeled exosomes were incubated
with anti-CD44, anti-CD49c and anti-CD104 to block the exosomal adhesion
molecule. These “antibody-blocked” exosomes were seeded on matrix protein
coated 96-well plates for 2h. Thereafter, the plates were washed to remove the
non-bound exosomes and the binding was measured by ELISA. The antibody
blocking of exosomal adhesion molecules significantly inhibited the exosome
binding. As shown in figure 9B, ASML exosome blocked with anti-CD44
hardly bind to collagen IV, laminin 111 and fibronectin , and particularly not to
hyaluronic acid, where the exosome binding decreased to one fifth compared to
non-blocked exosomes. ASML exosomes blocked with anti-CD49c showed
significantly weaker binding to fibronectin and laminin111. Furthermore, when
blocked with anti-CD104, binding of exosomes to laminin111 was most strongly
reduced (Figure 8B). Thus, I concluded that ASML exosomes selectively bind to
matrix proteins mainly through adhesion receptors. CD44 predominantly binds
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to hyaluronic acid and laminin111, CD49c to collagen IV, laminin111 and
fibronectin, and CD104 to laminin111.
Taken together, tumor-derived exosomes bind to various matrix proteins in a
non-random process, which relies on the composition of the stroma matrix as
well as the expression of exosomal adhesion molecules.
Figure 8. Adhesion molecule . (A) FACS and WB analysis of adhesion molecule expression in
ASML-wildtype (wt) and ASML-CD44v knockdown (kd) exosomes (B) Dye-labeled ASML
exosomes were pre-incubated with the indicated antibodies. Non-bound staining antibodies were
removed via centrifugation. The pellets were then collected and co-incubated with different pure
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matrix proteins that coated on ELISA plates for 2 hours at 4°C, and fluorescence intensity of binding
(% of total exosomes) was evaluated.
3.1.4 Exosomes bind to matrix proteins in vivo
Tumor exosomes binding and uptake is a non-random process. Thus, it became
interesting to investigate whether the ASML exosome also selectively bind to
specific tissue matrix.
To evaluate binding of exosomes to native tissue matrix in vivo, rats received an
i.v. injection of 400μg florescence dye-labeled ASML or ASML-CD44v
knockdown exosomes and were sacrificed after 48 h. Tissues were excised and
shock frozen. As shown in figure 9A, it is striking to find that the ASML
exosomes were present in many organs, such as tongue, colon, lung, and muscle,
and particularly in some tissue organ like skin and heart. Therefore, recovery of
exosomes implied ASML exosomes selectively bind to extracellular matrix in
vivo. This hypothesis was further explored by immunohistochemistry staining.
To determine whether ASML exosomes could bind to selective matrix proteins,
sections of shock frozen tissue samples were immuno-stained with matrix
protein specific antibodies and subjected to hematoxylin and eosin staining
(H&E). Confocal microscopy was performed with two different channels. One
fluorescence channel (FL-G) was used for evaluating the present of green
fluorescence dye-labeled exosomes, the other bright-field channel (BL-T) for
detecting expression of the indicated matrix proteins in different rat organs. The
digital overlays revealed that ASML exosomes (green) were specifically
enriched in the regions stained for defined matrix proteins (red parts). As shown
in figure 9B, ASML exosomes significantly bound to collagen IV in skeletal
muscle, to laminin 111 in heart muscle, and to vitronectin in the skin. In contrast,
ASML-CD44v knockdown exosomes were poorly discovered in these matrix.
These findings confirmed that ASML exosomes have a significant advantage in
binding to host matrix in vivo.
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Finally, to determine whether metastasizing tumor cells also take advantage of
exosome-matrix binding. The tumor preferentially metastasizes through the
lymphatic system to the lung, without invading the epidermis or forming a local
tumor nodule. However, occasionally muscle metastasis are observed, where an
example is shown in figure 9C. It is notable that ASML cells grew along the
basement membrane of the muscles without destroying the muscle. This fits to
basement membrane surrounding skeletal myofibers being strong attractants for
ASML exosomes.
Taken together, tumor exosome binding to selected matrix proteins appears to
attract tumor cells and promote their migration along with the tumor exosome-
decorated matrix. Thus, I proceeded to explore the impact and consequence of
exosome-binding to host matrix.
Discussion
51
Discussion
52
Figure 9. Tumor exosome bind to matrix proteins in vivo. (A and B) Dye-labeled ASML-wildtype
(wt) and ASML-CD44v knockdown (kd) exosomes (400 μg) were i.v. injected into rats, and rats were
sacrificed after 48 hours. Their organs were excised and then shock frozen and stained. These tissue
sections were counterstained with the hematoxylin and eosin (H&E). (A) The recovery of exosomes
was evaluated by Zeiss confocal microscopy. (B) The bright-field photo of confocal microscopy
presents immunohistochemistry of matrix proteins. The overlay of H&E staining and fluorescence by
image J demonstrates the distribution of dye-labeled exosomes and the co localization with the
indicated matrix proteins (scale bar, 10 μm). (C) ASML cells were intrafootpad injected into rats.
Tissue sections of the abdominal wall muscle were stained with control IgG or B5.5 (anti-α6β4; scale
bar, 20 μm).
3.2 CD44v6 cooperates with proteases in exosomes
Tumor derived exosomes are enriched in several proteases. The expression
profiles of proteases in ASML and -CD44v knockdown exosomes were
evaluated by WB and flow cytometry. ASML exosomes were abundant in uPAR,
MMP-2, MMP-3, MMP-9, MMP-13, MMP-14 (MT1-MMP) as well as
ADAM17 (TACE), ADAMTS1 and ADAMTS8. Similar to ASML exosomes,
ASML-CD44v knockdown exosomes also highly expressed MMP-2, MMP-14,
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ADAMTS1 and ADAMTS8. However, the expression level of uPAR, MMP-9
and TACE were around 35% less in -CD44v knockdown exosome than ASML
exosomes. Notably, MMP-13 had the most striking reduction, with only less
than 40% protein presented in -CD44v knockdown compare with ASML
exosomes (Figure 10, A and B).
The enrichment of proteases in exosomes may contribute to extracellular matrix
degradation. To support this hypothesis, the enzyme activities of MMPs were
evaluated by zymography. As CM-exo and exosomes are both secreted from cells,
I used CM-exo as a control to characterize the protease activity. As shown in
figure 10C, compared to CM-exo, the activity of MMPs was remarkably higher in
exosomes. ASML exosomes exerted a high expression level of pro-MMP-9
(97kDa) and active-MMP-9 (92kDa), as well as the MMP-2 (72kDa) level. On
the contrary, the activity of MMPs in ASML-CD44v knockdown exosomes was
strikingly reduced. This finding suggested that protease recovery in tumor
exosomes may correlated with the presence and association with CD44v6. Thus,
it became interesting to investigate whether exosomal proteases cleave and
degrade matrix proteins, at least partly, in a CD44v6 dependent manner.
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Figure 10. The recovery of exosomal proteases in dependence on the presence of CD44v6.
The protease expression in ASML-wt or -CD44v knockdown exosome was evaluated by (A)
WB and (B) flow cytometry. Significant differences between ASML-wt and -CD44v kd
exosomes are indicated by asterisk. (C) Zymography for evaluating MMP enzyme activities in
ASML and ASML-CD44vkd exosomes and CM-exo.
3.3 Matrix degradation by exosomal proteases
To determine the impact of exosomal proteases on the extracellular matrix,
purified matrix proteins and native host CM-exo were co-incubated with tumor
exosomes, and the degradation of matrix proteins was evaluated by WB.
Collagen I, collagen IV, fibronectin and laminin111 were significantly degraded
by ASML exosomes, while ASML-CD44v knockdown exosomes strikingly
reduce the capacity of matrix degradation. The degradation of collagen II
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displayed a similar level in both exosomes. However, vitronectin did not show
any degradation after co-incubation with ASML exosomes (Figure 11A).
I next estimated the degrading capacity of tumor exosomes on host matrix. The
CM-exo from LnStr, LuFb and RAEC lines served as targets for the exosomes. As
shown in figure 11B, the degradation patterns of the matrix proteins in the CM-
exo by tumor exosomes were distinct, which may be due to the different
compositions of the extracellular matrix delivered by LnStr, LuFb and RAEC
cells. As shown in figure 11B, laminin111 and laminin332 in LuFb CM-exo, as
well as collagen I in RAEC CM-exo were significantly degraded by ASML
exosomes, respectively, while these matrix proteins were barely degraded by
ASML-CD44v knockdown exosomes.
To confirm the contribution of exosomal proteases to matrix protein modulation,
the ASML exosomes were treated with MMP-2, MMP9/13 and TACE inhibitors,
respectively, to abolish the activity of exosomal proteases (Figure 11C). The
degradation of collagen I and collagen IV, particularly laminin332 were
significantly impaired after MMP-9/13 inhibitor and TACE inhibitor treatment,
but were only slightly affected after treatment with the MMP-2 inhibitor, it
means the modulation of these matrix proteins required MMP-9/13 and TACE.
Moreover, the cleavage of fibronectin specifically relied on TACE. Thus,
differences in exosome-mediate matrix modulation were strongly associated
with the interactions between CD44v6 and MMP-9, MMP-13 and TACE.
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Figure 11. Exosomal proteases contribute to matrix degradation. (A and B) Purified matrix
proteins and LnStr-, LuFb- and RAEC CM−exo were co-cultured with ASML-wildtype (wt) and
ASML-CD44v knockdown (kd) exosomes for 12h. Matrix degradation was evaluated for distinct
matrix proteins by blotting with antibodies to collagen I (coll I), collagen II (coll II), collagen IV (coll
IV), fibronectin (FN), vitronectin (VN), laminin111 (LN111) and laminin332 (LN332) (C) The matrix
protein degradation by tumor exosomes was inhibited by TACE, MMP2 and MMP9/MMP13
inhibitors. ASML-wt exosomes were co-incubated with protease inhibitors for 5h and co-cultured with
different matrix proteins for 12h. Matrix degradation was evaluated by WB.
Discussion
57
3.4 The engagement of exosomal CD44v6 in stroma cell adhesion
Adhesion of cells is regulated by their interaction with various components of
the extracellular matrix. Thus, it became important to determine whether the
tumor exosome-modulated host matrix affects stroma cell adhesion. First, the
protrusive activity of cells under different treatments was observed by confocal
microscopy. Stroma CM-exo, ASML exosomes and CM-exomodulated by ASML-
wt exosomes were co-cultured with LnStr, LuFb and RAEC cells respectively.
Figure 12A showed that the spreading of stroma cells increased significantly
when co-cultured with stroma CM-exo modulated by ASML exosomes as there
were more focal adhesion points. However, when co-cultured with ASML
exosomes, most stroma cells displayed less sprouts, particularly LuFb.
In addition, as shown in figure 12B, stroma cell adhesion increased to a
comparable level after treatment with autologous matrix or the ASML-CD44v
knockdown exosomes-modulated matrix, whereas stroma cells adhered more
significantly in the presence of the ASML exosomes-modulated matrix, The
results indicated that CM-exo modulated by tumor exosomes promoted cell
adhesion.
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Figure 12. The tumor exosome-modulated matrix and host cell adhesion. (A) LnStr, LuFb,
and RAEC cells were seeded on cover slides coated with BSA, autologous CM-exo, ASML-wt
exosomes and exosome-modulated CM-exo, and were stained with anti–CD44 and phalloidin
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fluorescein isothiocyanate. Confocal microscopy of representative examples (scale bar,
100μm) (B) BSA, CM-exo, or ASML-wt or ASML-CD44vkd exosome-modulated CM-exo were
pre-coated in 96-well plates overnight. LnStr, LuFb, and RAEC lines were seeded in these
plates for 2h, and washed 2 times to remove the non-bound cells. Adhesion was evaluated by
crystal violet staining of adherent cells. The mean± SD of the percent adherent cells is shown.
Significant differences between cells adherent to stroma matrix and the exosome-modulated
matrix are indicated by asterisk.
3.5 Tumor exosome-modulated matrix contribute to stroma cell motility
Extracellular matrix modulation could facilitate tumor invasion and migration so
as to promote tumor metastasis. As I found that tumor exosomes signficantly
modulated the matrix components, I wondered whether the stroma matrix
modulated by the tumor exosomes could better serve the demands of
metastasizing cancer cells.
3.5.1 Migration
The transwell chamber assay was used to evaluate the impact of tumor the
exosome-modulated matrix on cell migration. LnStr, LuFb and RAEC cells were
seeded in the upper part of Boyden chambers, with the lower parts containing
2% BSA as a negative control, 20% FCS as the positive control, stroma cell
autologous CM-exo, exosomes from the ASML or -CD44v knockdown cells and
tumor exosome-modulated CM-exo. The numbers of migrating cells through the
membrane were counted after 16 h. As shown in figure 13A, the transwell assay
revealed that stroma cells co-cultured with ASML or -CD44v knockdown
exosomes hardly strengthened the migration capacity. However, more than 50%
of stroma cells migrated, when their autologous CM-exo was modulated by
ASML exosomes while stroma cells co-cultured with autologous matrix or -
CD44v knockdown exosome-modulated CM-exo showed a lower migration rate.
To confirm this finding, a wound healing assay was performed. stroma cell
monolayers were scratched and co-cultured with ASML or -CD44v knockdown
exosomes. Images were captured at the starting point and at regular intervals
during cell migration. As in this setting, the host cell matrix was continuously
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exposed to tumor exosomes during the observation time, the impact of tumor
exosomes on stroma CM-exo modulation was directly evaluated. As shown in
figure 13B, stroma cell migration was strongly accelerated in the presence of
ASML exosomes, particularly for LnStr and RAEC. Thus, migration of LnStr,
LuFb and RAEC was strengthened only when their autologous CM-exo
modulated by ASML exosomes.
Finally, the migration route of single cell was evaluated by live-cell video
microscopy for LnStr and LuFb lines lasting 12h. As described, the stroma CM-
exo was treated with ASML or -CD44v knockdown exosomes, and stroma cells
were co-cultured either with these altered CM-exo or directly with tumor
exosomes (Figure 13C). Stroma CM-exo treated with ASML exosomes
significantly promoted LnStr and LuFb migration, whereas stroma cells treated
with exosomes or stroma CM-exo treated by ASML-CD44v knockdown
exosomes showed unaltered migration.
Taken together, tumor exosomes can modulate the stroma matrix to promote cell
migration. This obviously depends on the exosomal CD44v6 as ASML-CD44v
knockdown exosomes exerted very weak effects, which might be due to the
weaker binding and the lower amount of proteases for matrix degradation.
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Figure 13. The tumor exosome-modulated matrix supports host cell migration. (A) stroma cells
were seeded in the upper part of Boyden chambers. The lower parts contained BSA, 20% FCS, or CM-
exo pretreated with ASML-wt or –CD44v knockdown exosomes. Migration was evaluated after 16
hours by crystal violet stain onto the lower membrane site. (B) Cells were seeded on plates coated with
CM-exo or tumor exosome-modulated CM-exo. Subconfluent monolayers were scratched by pipette tips
and observation followed for 26 hours. Representative examples (scale bar, 250 μm) and the mean ±
SD (three wells) are shown. (C) Cells were seeded on CM-exo or exosome-modulated CM-exo. Cell
migration was observed for 12 hours. Representative examples and the mean value ± SD track of 15
cells per 20 minutes are shown. (A-C) Significant differences in stroma cell migration by exosomes
treatment are shown or indicated by asterisk.
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3.5.2 Invasiveness
Cell invasiveness is related to cell migration. However, it requires a cell to
migrate through a barrier of extracellular matrix by enzymatic degradation. To
evaluate whether the invasiveness of stroma cell could be influenced by tumor
exosomes, I performed the matrigel transwell assay. Matrigel was co-incubated
with ASML or ASML-CD44v knockdown exosomes overnight for degradation
and remodeling. LnStr, LuFb, and RAEC were seeded on untreated or
exosomes-modulated matrigel for 24h. The penetration of stroma cells was
shown by crystal-violet staining and the number of invading cells was counted
by image J. As shown in figure 14A, the invasion capacities of LuFb and RAEC
were significantly increased when seeded on ASML exosome-modulated
matrigel. However, ASML-CD44v knockdown exosomes exerted a much
weaker effect. Furthermore, LnStr hardly invaded the matrigel spontaneously,
but passed through it when the matrigel was degraded by ASML exosomes. The
matrigel modulated by ASML-CD44v knockdown exosomes only slightly
supported LnStr invasiveness.
These in vitro findings were strongly supported by an in vivo matrigel plug
assay (Figure 14B). BDX rats were s.c. injected with matrigel mixed with
ASML or -CD44v knockdown exosomes. After 5 days, the plug was removed
and shock frozen. Plug sections were stained with antibodies for the indicated
matrix proteins, integrin (anti-CD49c) as identify marker, or fibroblasts
(vimentin) and endothelial cells (CD31). CD49c+, vimentin+ and CD31+ cells
as well as the indicated matrix proteins were only abundantly recovered in
ASML exosome-treated plugs, while collagen I and vimentin were also
recovered at a low level in ASML-CD44v knockdown-treated plugs. Thus,
ASML exosomes exerted a more pronounced effect on matrix than -CD44v
knockdown exosomes. To sum up, exosomal CD44-protease complexes can
facilitate host cell migration and invasiveness evidently through remodeling and
degradation of the target matrix.
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Figure 14. Tumor exosome-modulated matrix promotes invasiveness. (A) Matrigel mixed with the
RPMI medium or tumor exosome. Representative different examples (scale bar, 200 μm) and the
value mean numbers (triplicates) ± SD of penetrating cells are indicated. Significant differences
between matrigel and tumor exosome-pretreated matrigel are indicated. (B) Matrigel was mixed (1:1)
with PBS, which contained ASML or ASML-CD44v knockdown exosomes. The plug was removed
after 5 days and was shock frozen. (scale bar, 200 μm).
3.6 The tumor exosome-modulated matrix facilitates cell proliferation
The tumor matrix, inherently modulated by autologous exosomes, exerted a
feedback on the tumor cells by increasing tumor cell proliferation and apoptosis
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resistance (Jung et al, 2011). Thus, it became essential to explore whether
besides promoting cell motility, the tumor exosome-modulated host matrix also
activates non-transformed cell proliferation.
First, the stroma cell lines LnStr, LuFb and RAEC, as well as lymph node cells
(LNC) and bone marrow cells (BMC) were co-culture with ASML or -CD44v
knockdown CM-exo, and the proliferation of these cells was evaluated by 3H-
thymidine incorporation. As shown in figure 15A, ASML CM-exo significantly
promoted LuFb proliferation, while it had only a mild effect on LnStr, LNC and
BMC, and did not influence RAEC proliferation. Compared with ASML CM-exo,
ASML-CD44v knockdown CM-exo hardly affected LnStr, LuFb and LNC cell
proliferation.
Surprisingly, in contrast to tumor CM-exo, ASML exosomes displayed an even
stronger effect on LnStr, LuFb, and RAEC proliferation (Figure 15B). For
instance, the proliferation of LnStr increased 3-fold after co-incubation with
autologous CM-exo modulated by ASML exosomes.
Accelerated cell proliferation might be accompanied by up-regulation of growth
factor receptors and activation of downstream signaling pathways. As shown in
figure 15C, when co-cultured with ASML exosome-modulated CM-exo, LnStr
and LuFb expressed a higher level of epidermal growth factor receptor (EGFR)
and chemokine receptor 4 (CXCR-4), particularly the vascular endothelial
growth factor receptor 1 (VEGFR1). However, CM-exo modulated by ASML-
CD44v knockdown exosomes only promoted the slightly fibroblast growth
factor receptor present in LnStr, and VEGFR1 expression in LnStr and LuFb.
Furthermore, the PDGFR also changed, which was particularly associated with
LuFb growth, was much higher when the cells were co-cultured with ASML
exosome modulated LuFb CM-exo.
In addition, the autologous CM-exo, several growth promoting signaling cascades
were activated by the ASML exosome-modulated CM-exo particularly
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extracellular signal-regulated kinase 1/2(ERK1/2), as well as other signaling like
c-jun (Figure 15D). In LuFb the effect was much stronger than in LnStr. The
distinct impact on these two cell lines might be due to the different amount of
growth factor delivered by these cells into the extracellular matrix. Thus,
activation of signaling cascades by tumor exosome-modulated matrix may be
initiated by liberation of growth factors in the extracellular matrix. To sum up,
the effect of the ASML exosome-modulated matrix differs for individual target
cell lines likely due to the accessibility of matrix-deposited growth factors and
forced liberation by the tumor exosome-modulated matrix.
Figure 15. The tumor exosome-modulated matrix promotes cell proliferation. (A and B) Cells
were treated with CM, CM−exo, or tumor exosomes pretreated CM−exo. Cell proliferative activity was
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evaluated by the assay of 3H-thymidine incorporation after 3 days of culture. (C) Flow cytometry
analysis of LnStr and LuFb that were treated with CM−exo w/wo ASML-wt or -CD44v knockdown
exosomes. Mean values (three assays) of stained cells are shown. (D) LnStr and LuFb expression
check by flow cytometry. (E) WB analysis of cytokines and chemokines in LnStr, LuFb, and RAEC
CM−exo. (A-D) Significant differences in the presence of tumor exosomes or tumor exosome-
modulated CM-exo are indicated by asterisk.
3.7 The tumor exosome-modulated matrix affects apoptosis
To clarify whether the tumor exosome-modulated host matrix can also procet
target cells from apoptosis, stroma cells were co-cultured with tumor matrix or
tumor exosome-modulated host matrix and stained with AnnV/PI and analyzed
by flow cytometry after 3 days of culture in the presence of cisplatin. As shown
in Figure 16A, ASML wild type CM−exo displayed a mild apoptosis-protective
effect on LnStr, LuFb and RAEC, but not on LNC or BMC. The ASML-CD44v
knockdown CM−exo exerted no protective effect on host cells. However, when
LnStr and LuFb CM-exo were pre-treated with ASML exosomes and then co-
cultured with their originating cells, AnnV/PI staining revealed that the ASML
exosome-modulated stroma CM-exo exerted a stronger protective effect than the
autologous matrix. Particularly, for LnStr, the apoptotic rate decreased 40%
compare with control cells (Figure 16B).
Although the underlying mechanism is still poorly elucidated, we figured out
that the ASML exosome-modulated LnStr CM-exo provided signals to enhance
the phosphatidylinositol 3-kinase (PI3K)/Akt pathway activation along with the
liberation of apoptosis regulator Bcl-2 family. As shown in figure 16C, after
induction of cell apoptosis by cisplatin, B-cell lymphoma 2 (Bcl2), B-cell
lymphoma-extra large isoform1 (BclXl) as well as Bcl-2-associated death
promoter (BAD) phosphorylation were upregulated in LnStr cells co-cultured
with ASML exosome modulated CM-exo. On the other hand, the expression of
other pro-apoptotic molecules like Bcl-2-associated X protein (Bax) and Bcl-2
homologous killer (Bak), cleaved caspase-9, and activated caspase-3 were
decreased. In contrast, LnStr cells which were co-cultured with autologous CM-
exo as well as the ASML-CD44v knockdown exosome-modulated CM-exo only
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induced sightly changes in PI3K, Bcl2 and BclXl expression, which resulted in
the reduced apoptosis resistance. Further studies should focus on the initial
trigger which was delivered by tumor exosome-modulated matrix that support
the activation of the PI3K/Akt pathway.
Figure 16. The tumor exosome-modulated matrix can support drug resistance. (A and B)
stroma cells were co-incubated with ASML CM or tumor exosome-pretreated autologous CM-
exo. Apoptosis resistance was evaluated by AnnV/PI staining after 3 days of culture. (C) Cells
were incubated for 24 hours with CM-exo or tumor exosome-pretreated host CM-exo, where
indicated cultures contained 10 μg/ml cisplatin. Cells were fixed and permeabilized, and
evaluated by FACS flow cytometry, and mean values (three assays) are shown. (C)
Significant differences between host CM-exo and tumor exosome-pretreated CM-exo are
indicated by asterisk.
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4. DISCUSSION
Exosomes mediate intercellular communication through transportation of their
bioactive molecules including enzymes, receptor proteins, mRNA and
microRNA. For tumor exosomes, it has been demonstrated that their crosstalk
with the host considerably contributes to tumor progression. This was elaborated
particularly for the influence of tumor exosomes crosstalk with stroma cells in
(pre) metastatic organs. I report here that, apart from the crosstalk with host cells,
tumor exosomes also affect the extracellular matrix and that the exosome-
modulated host matrix also has great impact on tumor progression. Using a
highly metastatic rat pancreatic cancer line, ASML, I demonstrated that tumor
exosomes directly bound to and degraded host matrix via exosomal adhesion
molecules and proteases. Notably, I also show for the first time that the ASML
exosome-modulated matrix strongly supports stroma cell motility and facilitates
proliferation and apoptosis resistance. Last, but not least, I could elaborate a
major role of exosomal CD44v6 in host matrix modulation.
4.1 The choice of tumor exosomes
BSp73 is a pancreatic adencarcinoma that consists of two sublines, the non-
metastatic BSp73 AS line and the highly metastatic BSp73 ASML line (Matzku
et al., 1983). The latter differs from the non-metastatic line by expression of
CD44 variant v4-v7 (CD44v). CD44v expression suffices to initiate the
metastatic phenotype (Günthert et al., 1991). The role of the CD44v in
metastasis was confirmed by the loss of the capacity to metastasize of ASML
cells with a CD44v knockdown (Klingbeil et al., 2009). Our previous study also
demonstrated that CD44v6 is sufficient for assembling a soluble matrix, which
allows tumor exosomes to modulate the pre-metastatic organ to facilitating
tumor cell embedding and growth (Jung et al., 2009).
The availability of a metastatic line and a non-metastatic line that differed only
in the expression level of CD44v6 together with their corresponding exosomes
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provided a good tool to evaluate the impact of metastatic tumor cell derived
exosomes on the host matrix and the contribution of CD44 variant isoforms in
tumor metastasis.
4.2 Tumor exosomes bind to the host matrix
Exosomes constitutively express tetraspanin proteins and several membrane
proteins (e.g. CD44), which are responsible for the binding selectivity of
exosomes (Rana et al., 2012; Rana and Zöller 2011). Apart from binding to the
target cells, ASML exosomes could also bind to extracellular matrix proteins.
To study the molecular function of exosomal CD44v6 in the crosstalk between
tumor exosomes and native host matrix (including extracellular matrix proteins),
I evaluated and compared the different binding efficiency of ASML and ASML-
CD44v knockdown exosomes.
Notably, the binding capacity of ASML exosomes to hyaluronic acid, collagen I,
-IV, fibronectin and laminin 111 was stronger than that of ASML-CD44v
knockdown exosomes. As CD44 could bind to via associated integrins, I
performed antibody blocking assay. These experiments revealed that tumor
exosomes bound to laminin 111 mostly through integrin α3 and α6β4, to
collagens predominantly through α3, and to hyaluronic acid through CD44.
Thus, the lower binding efficiency of ASML-CD44v knockdown exosomes to
the extracellular matrix components is probably due to the decreased expression
of exosomal CD44v6 and its associated integrin α6β4.
Further more, in vivo experiments indicated that ASML exosomes preferentially
bound to selected matrices. ASML exosomes preferential bound to muscles, the
perivascular region, the submucosa of the gastrointestinal tract, and the basal
lamina of the skin. Tissue staining for matrix proteins revealed that preferred
targets of ASML tumor exosomes were collagen IV, fibronectin and laminins,
which are also preferred targets of CD44v6 and its associated integrins. A first
hint toward the biological significance of tumor exosomes binding to selective
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tissue matrix came from the finding that ASML cells, which metastasize
preferentially via lymph nodes to the lung, occasionally grow along tissue
matrix (e.g. muscle and skin), without destructing or invading the adjacent tissue.
Take together, ASML exosomes bind to selective matrix components via
adhesion molecules which are engaged in exosomal CD44v6 protein complexes.
The reduced expression of α6β4 and CD44v6 in ASML-CD44v knockdown
exosomes mainly accounts for the weak binding.
4.3 Exosomal proteases and CD44v6 contribute to matrix degradation
Exosomes contain large amount of proteases, some of which are known to
associate with CD44 or are regulated by CD44 (Hakulinen et al., 2008; Jung et
al., 2009; Alderton et al., 2012). CD44 not only directly binds to several
proteases (Fayard et al., 2009), but also serves as a platform where proteases are
brought together with their substrates (Hakulinen et al., 2008; Samnegard et al.,
2002; Xu et al., 2010). It is well known that MMP-9 is recruited to the cell
surface by docking to CD44 (Yu et al., 2002). In addition, the stimulation of
CD44 by its ligand hyaluronic acid could up-regulate uPA and uPAR expression
(Bourguignon et al., 2012). Then, the question arose, whether tumor exosomes
degrade extracellular matrix proteins or the host matrix, and whether exosomal
CD44v6 contributes to matrix protein degradation.
Indeed, the expression level of uPAR, MMP-9, MMP-13, and TACE are higher
in ASML exosomes than in ASML-CD44v knockdown exosomes. Zymography
confirmed the high level of MMP-9 activity in ASML exosomes, and strongly
impaired enzyme activity in CD44v6 deficient exosomes. Differences in
exosomal protease expression were accompanied by pronounced difference in
the degradation of collagen I, collagen IV, fibronectin and laminin111. The
contribution of individual proteases was verified by the use of protease
inhibitors. It is found that MMP-9 expression accounted predominantly for
collagen I, collagen IV and laminin332 degradation, and TACE expression
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particularly for fibronectin degradation. Importantly, these two proteases are
associated with CD44v6 and are hardly expressed in the ASML-CD44v
knockdown exosomes. Thus, poor matrix degradation correlates with the lack of
CD44v6 and its associated proteases.
One additional point should be mentioned, CD44v6 also associates with
integrins α3β1 and α6β4, which are adhesion ligands for matrix proteins. Thus,
the exosomal proteases evidently profit from focalization of proteases at
adherent points, which facilitates matrix degradation. I found that exosomal
MMP-9, MMP-13, uPAR and TACE, which are regulated by CD44v6,
contribute to the modulation of the host matrix.
4.4 Host matrix modulation by tumor exosomes supports cell motility
Controlled degradation of extracellular matrix components is essential for
regulating biological effects on host cells. For instance, after cleavage and
degradation, some laminin fragments promote cell motility (Malinda et al., 2008;
Kim et al., 2011), and small hyaluronic acid fragments facilitate induction of an
inflammatory milieu (Tienthai et al., 2003). Thus, tumor exosomal proteases
may not only be responsible for matrix protein degradation, but also initiate new
activities by releasing biologically active molecules from the extracellular
matrix.
Indeed, the host matrix that was modulated by ASML exosomes could promote
stroma cell migration, whereas ASML-CD44v knockdown exosome-modulated
matrix did not. Beyond migration, ASML exosomes also allowed host stroma
cells to invade this modulated matrix. In line with the lower efficiency of
ASML-CD44v knockdown exosomes in degrading matrix proteins, host cell
invasiveness was hardly affected by the ASML-CD44vkd exosome-modulated
host matrix.
The findings in my study provide strong evidence that tumor exosomes facilitate
host cell motility and invasiveness not only by directly affecting host cells, but
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also by modulating the host matrix. These findings expand the range of known
tumor exosomes activities and explain some confusing phenomena, such as the
tumor-induced stroma reaction, which is common in pancreatic cancer (Epifano
et al., 2002;Erkan et al., 2012), the recruitment of endothelial cells (Umezu et
al., 2013), and the recruitment of hematopoietic progenitors towards the tumor
cells (Vogel et al., 2012). Additional work is required to elaborate whether this
is only due to the biologically active matrix degradation products, or whether the
liberation of matrix protein-deposited proteases, growth factors and
cytokine/chemokine also contributes to host cell motility.
4.5 Host matrix modulation by tumor exosomes affects cell proliferation
and apoptosis resistance
Extracellular matrix also sequesters and locally releases growth factors, such as
epidermal growth factor (EGF), fibroblast growth factor (FGF) and other
signaling molecules (Hynes et al., 2009; Ge et al., 2012). In addition, CD44
interacts with some of the molecules deposited in the extracellular matrix, which
triggers activation of signal transduction and subsequent cell proliferation (Jung
et al., 2009; Thuma and Zöller et al., 2014; Orian-Rousseau, 2010). Therefore, I
wondered whether the tumor exosome-modulated host matrix could affect target
cell proliferation.
The up-regulation of these growth factor receptors could support the activation
of the mitogen-activated protein kinases (MAPK) (Hynes et al., 2009), as well
as the phosphoinositide 3-kinase/Akt pathways (Bryant et al., 2005). Another
up-regulated molecule, tumor growth factor-β (TGFβ) activates the c-Jun N-
terminal kinases (JNK), MAPK and the nuclear factor-κ of activated B-cells
(NFκB) pathways (Holmes et al., 2007;Dey et al., 2010). These signaling
pathways, when activated, could promote target cell proliferation. Indeed, I
found that ASML exosomes modulated host matrix promoted stroma cell
proliferation.
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Interestingly, I found that the pronounced PI3K and Akt phosphorylation, Bad
phosphorylation and Bcl-2 expression were also up-regulated in the stroma cells
after incubation with ASML exosome-modulated matrix. In line with this
observation, expression of the caspase-3 became only mildly up-regulated by
cisplatin treatment, and the cleavage of caspase-9 was significantly reduced
when stroma cells were co-cultured with the ASML exosome-modulated matrix.
It is important to note that the bioavailability of growth factor is regulated by the
extracellular matrix stiffness (Hynes 2009; Brizzi et al.,2012), which is
regulated and modulated by proteases (Marhaba et al., 2005; Bryant et al., 2005).
For instance, activation of EGFR signaling requires TACE to expose the
ectodomain of EGFR to its ligands (Urban et al., 2002; Tsruya et al., 2002). As
the exosomal proteases (e.g. MMP-9 and TACE) are regulated by CD44v6, it is
reasonable to make the conclusion that the contribution of exosomal CD44v6 in
modulating the extracellular matrix may rely on the CD44v6-associated
proteases that facilitate liberation of ligands for stroma cells (Zoller 2009).
It already be well accepted that the binding and uptake of tumor exosomes can
stimulate and reprogram host cells (Hakulinen et al., 2008; Park et al., 2010). I
here present evidence that exosomes affect the host matrix and that the exosome
modulated host matrix in a feedback loop contributed to stroma cell activation.
ASML exosomes, which highly express CD44v6, α6β4 and MMP-9 and TACE,
supported an intense crosstalk between the pancreatic cancer cells and the
pancreatic tissue stroma. These tumor exosomal molecules also directly or
indirectly modulate stroma matrix. Finally, the modulated stroma matrix and the
liberated growth factors generate a milieu that favors stroma cell and
hematopoietic cell recruitment, motility, activation and apoptosis resistance. As
exosomes impact on matrix modulation can equally affect the local tumor
microenvironment, the hematopoietic system and pre-metastatic organs.
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5. Conclusion and Outlook
Conclusion
Tumor exosomes communicate with their originating tumor cells as well as host
stroma cells, endothelial cells and hematopoietic progenitor cells. Up to date,
researches have proved that tumor exosomes bind to and are uptake by target
cells, which significantly alter target cells. I here certify that tumor exosome also
modulate the host extracellular matrix and thereby promote host cell motility,
proliferation and apoptosis resistance. From my research, I could make several
conclusions about the functions of tumor exosomes.
First, tumor exosomes bind to selected matrix proteins in a non-random manner
in vitro and in vivo. Tumor exosomes further modulate the host matrix through
exosomal proteases. The extracellular matrix is important for bioactive
compound storage and tissue repair, as well as for the cross-talk between tumor
and stroma cells (Sangaletti et al., 2008). Taking this into account, the host
matrix modulated by tumor exosomes supports creation of space, liberation of
cytokines/chemokines and proteases and generation of cleavage products that
promote stroma cell activation.
Second, besides understanding the effect of tumor exosomes on the host
extracellular matrix modulation, I focused on the special contribution of
exosomal CD44v6. CD44v6 is involved in a multitude of functions of the
exosomes, which is evidenced by the fact that tumor exosomes derived from
ASML-CD44v knockdown cells exerted only a very weak capacity to modulate
host matrix and stroma cells. I confirmed that CD44v6 in complexes with MMP-
9, uPAR and TACE are particularly important for matrix protein degradation.
Taken together, exosomal CD44v6 binds extracellular matrix components and
interacts with several proteases that are pivotal in matrix modulation.
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Outlook
Although I started to characterize potential functions of exosomes and exosomal
CD44v6 in the modulation of the extracellular matrix, there remains several
questions that need to be addressed.
First, I reported the impact of CD44v6-competent tumor exosomes on the host
stroma matrix or cells. It might still requires a detailed proteome analysis of
stroma modulation and a correlation of the modulated individual stroma
components with the stroma cell response.
Second, exosomes can directly activate stroma cells and can be uptaken by
stroma cells. The impact of CD44v6-competent tumor exosomes on stroma cell
activation remains to be explored. The uptake of CD44v6-competent tumor
exosomes by stroma cells has a significant impact on stroma cell reprogramming,
which is at least partly due to the transfer of miRNA (Rana et al., 2013).
However, reprogramming of host cells by CD44v6-competent tumor exosomes
remains to be comprehensively analyzed. Notably, there is evidence that
CD44v6 is also engaged in the recruitment of miRNA into exosomes. Further
experiments are required to define the mode of miRNA recruitment by CD44v6.
Also, reprogramming of host cells by CD44v6-competent tumor exosomes has
not been comprehensively analyzed. Finally, activation of signaling cascades in
stroma cells by CD44v6-competent exosomes remains to be explored.
Third, CD44v6 is a cancer-initiating cell marker. There is evidence that CIC
exosomes transfer CIC features, particularly the capacity for EMT towards non-
CIC. An engagement of CD44v6 was postulated, but needs confirmation.
Taken together, the function of tumor exosomes in inducing metastasis and the
strong engagement of CD44v6 in this process demand further exploration in
hope for therapeutic intervention via a blockage of CD44v6-competent tumor
exosome activities.
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6. Summary
Tumor-derived exosomes, recognized as important intercellular communicators
in the cancer microenvironment, facilitate tumor development and metastasis.
Several groups have reported on the crosstalk between exosomes and their target
cells in tumorigenesis and tumor progression. However, the question whether
exosomes affect the extracellular matrix was largely neglected. Previous
researches suggested that CD44v6 interacts with matrix proteins and that
CD44v6 might be responsible for functional activities of tumor exosomes. Thus
I hypothesized that tumor exosomes modulate the host matrix, such that it
facilitates tumor progression in a CD44v6-dependent manner.
To approach this topic, I used exosomes from the highly metastatic rat
pancreatic adenocarcinoma ASML and the poorly metastatic ASML CD44v6
knockdown cell lines. The binding of ASML exosomes to individual
extracellular matrix components was higher than ASML-CD44v6 knockdown
exosomes in vitro and in vivo. Preferential targets of tumor exosomes vary with
the expression profile of exosomal adhesion molecules. In ASML exosomes,
high CD44v6 expression is essential for hyaluronic acid binding, and high
integrin α6β4 expression accounts for laminin 332 binding.
Tumor exosomes binding to matrix is accompanied by significant modulation of
the extracellular matrix through exosomal proteases. The matrix proteins
including collagens, laminins, fibronectin and hyaluronic acid were degraded
after the binding of ASML exosomes. The particular contribution of CD44v6
relies on affecting the transcription of uPAR and the association of proteases
including MMP-9, MMP-14 and TACE. Degradation of the extracellular matrix
via these proteases was confirmed by using protease inhibitors.
The host extracellular matrix modulated by ASML exosomes promoted stroma
cell adhesion, migration and invasiveness. These effects were not or weakly
induced by host matrix modulated by ASML-CD44v6 knockdown exosomes.
Summary
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Degradation of the matrix proteins is also accompanied by liberation of growth
factors and chemokines.
Taken together, modulation of the extracellular matrix by tumor exosomes is a
critical factor in the cross-talk between a tumor and the host. Thus, I suggest that
modulation of the extracellular matrix by exosomes may also be important in
organogenesis, vasculogenesis, angiogenesis, and tissue repair including wound
healing and clotting after vessel disruption.
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